CIB1: A promising target in triple-negative breast cancer by Chung, Alexander
 
CIB1: A PROMISING TARGET IN TRIPLE-NEGATIVE BREAST CANCER 
 
Alexander Huey Chung 
 
A dissertation submitted to the faculty at the University of North Carolina at Chapel Hill in partial 
fulfillment of the requirements for the degree of Doctor of Philosophy in the Department of 





 Approved by: 
 Leslie V Parise 
 Channing Der 
 Gary Johnson 










































Alexander Huey Chug 






Alexander Huey Chung: CIB1: A promising target in triple-negative breast cancer 
(Under the direction of Leslie V. Parise) 
 
 
CIB1 is a viable cancer target and depleting CIB1 causes selective cancer cell death. My 
thesis work focuses on understanding the cell death mechanisms upon CIB1 depletion. In this 
study, we explore the effects of depleting CIB1 in triple-negative breast cancer (TNBC) cells in 
combination with chemotherapy and determined the underlying mechanisms behind the specific 
killing of cancer cells. 
 
TNBC is defined by a lack of targetable cell surface receptors – estrogen, progesterone, 
and HER2. To date, no targeted therapies are clinically approved; the standard of care for 
TNBC patients is limited to surgery and chemotherapy. Here, we introduce novel combinations 
of CIB1 depletion with docetaxel and TRAIL that result in significantly enhanced cell death via 
death receptor-mediated apoptosis and paraptosis, a non-apoptotic mode of cell death in TNBC 
cells. Additionally, the combination treatments activated both cell death mechanisms in 
docetaxel-resistant TNBC cells. In contrast, CIB1 depletion alone or with either docetaxel or 
TRAIL spared normal breast epithelial cells from both apoptotic and paraptotic cell death. The 
results collectively demonstrate investigation of cell death mechanisms for future design of safe, 
efficacious combination therapies for TNBC. 
 
CIB1 regulates PI3K-AKT and MEK-ERK oncogenic pathways that drive TNBC 
tumorigenesis. However, the signaling cascades that connect CIB1 to these oncogenic 
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pathways are not fully understood. To further understand the signaling network surrounding 
CIB1, we collaborated with the laboratory of Dr. Xian Chen to profile CIB1-depleted TNBC cells 
via phosphoproteomic analysis. Using TNBC cells that are sensitive (MDA-468) and insensitive 
(MDA-231) to CIB1 depletion, our goal was to uncover additional CIB1-dependent signaling 
pathways. The analysis generally revealed significant differences in protein activities upon CIB1 
depletion in MDA-468 compared to the insensitive MDA-231 cells. More specifically, we found 
increased SHIP2 and PP2A activities in CIB1 depleted MDA-468, later validated by 
phosphatase assay. While it is unclear as to whether CIB1 depletion-induced increase in PP2A 
and SHIP2 phosphatase activity is important for regulating AKT and ERK activities, their roles 
as scaffolding proteins remain to be explored. Taken together, my results further validate CIB1 
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Chapter 1: Introduction 
1.1 Triple-negative breast cancer (TNBC) 
 
Breast cancer is the second leading cause of cancer-related death among women in the 
United States, who have a 1 in 8 chance of being diagnosed with the disease at some point 
during their lifetime (Cancer Statistics Review, NCI). Because breast cancer is globally 
widespread, there has been an abundance of research to understand the biology of the disease 
in order to optimize clinical intervention. Pathologically, breast cancer is known to arise from 
epithelial cells that form lobular units within the mammary gland that are commonly referred to 
as the terminal duct lobular unit (TDLU) (1). The TDLU is composed of an inner layer of luminal 
epithelial and an outer layer of basal myoepithelial cells (1, 2). The cell-of-origin for breast 
cancer was long believed to reside in the stem cell niche in the inner layer of the TDLU. 
Interestingly, pluripotent stem cells of luminal lineage in the inner TDLU layer were shown to 
differentiate into both luminal and basal myoepithelial cells, suggesting that both types of cells 
are related (3, 4). Basal myoepithelial cells are located in the outer layer of the TDLU, allowing 
contact with the extracellular collagen-rich stroma. Due to this localization, basal myoepithelial 
cells may serve as a bridge for breast cancer cells to invade into extracellular stroma and initiate 
metastasis (5). Therefore, the basal myoepithelial lineage has also gained interest as a culprit 
for initiating lesions during tumorigenesis. 
 
Of the estimated 230,000 new cases of breast cancer reported each year in the U.S., 
15-20% are diagnosed as triple-negative breast cancer (TNBC) (6, 7). This subtype of breast 
cancer is particularly aggressive with poor prognosis and mostly arises from the basal 
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myoepithelial lineage (7). Molecularly, TNBC is a subtype characterized by a lack of estrogen, 
progesterone, and HER2 reception expression (6, 7). The explosion of omics-based studies 
since the early 2000s has led to expanding breast cancer subtypes based on transcriptional 
signatures: basal-like, HER2-enriched, luminal A, luminal B, and normal-like (8, 9). Although 
TNBC mainly overlaps with the basal-like transcriptional signature, TNBC itself is molecularly 
heterogeneous and histopathologically distinct. Initially, TNBC was molecularly classified as 
“BRCAness” referring to germline mutations in BRCA1 and BRCA2 (10). Dysfunctional BRCA 
leads to impaired DNA repair machinery and high rates of genomic instability, rendering 
sensitivity to the standard-of-care chemotherapy (11-13). However, upon whole-genomic 
analysis, molecular classification of TNBC turned out to be more complex, with 5 molecularly 
distinct subtypes: Basal-like (BL1 and BL2 of myoepithelial origin), mesenchymal-like, 
mesenchymal stem-like, luminal androgen receptor expression, and immunomodulatory (14-16). 
Each subtype of TNBC harbors unique oncogene alterations and responds differently to 
chemotherapy. The improved molecular understanding of TNBC has led to formulating novel 
targeted therapies for TNBC subtypes that are relatively unresponsive to chemotherapy. 
 
1.1.1 Standard-of-care chemotherapy, irradiation and surgery 
	
As mentioned above, TNBC lacks targetable markers – estrogen, progesterone, and 
HER2 receptors (6, 7). Therefore, treatment options for TNBC patients are limited to 
chemotherapy and surgery, which have shown modest overall response rates (17, 18). Here, I 
briefly summarize commonly used chemotherapeutic agents currently being used to treat TNBC 
patients. 
 
Clinicians often elect to treat TNBC patients by surgery in the form of either mastectomy or 
lumpectomy. A less invasive procedure in breast conservative surgery was found not to cause 
higher rates of local recurrence, making surgical options viable for patients (19). Other than 
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surgery, radiotherapy is also one of the first-line treatment options for TNBC patients. 
Radiotherapy is often combined with surgery as an adjuvant regimen to eradicate localized 
breast tumors. However, the rapid growth and highly metastatic nature of TNBC poses 
challenges for these localized approaches of treatment from achieving complete responses 
(20). Therefore, a systemic approach via chemotherapy has been subject to rigorous testing to 
improve therapeutic outcomes.  
 
For instance, platinum-based chemotherapy is commonly used for metastatic TNBC 
patients, but the response rate is modest (21, 22). Mechanisms of actions of platinum-based 
chemotherapeutic agents such as carboplatin and cisplatin involve crosslinking with purine 
bases to halt DNA replication (23). Because carboplatin and cisplatin induce DNA damage, 
patients with mutations in DNA repair machinery BRCA1/2 were shown to respond at a 
significantly higher rate (24).  
 
Standard adjuvant and neoadjuvant chemotherapeutic regimens for TNBC patients 
involve administration of taxane (25). Taxane is a class of drugs derived from natural product 
that includes paclitaxel and docetaxel, the latter with higher potency (26). Molecularly, taxanes 
bind to and stabilize microtubules thereby disrupting mitosis during cell cycle (27). Anthracycline 
is another class of chemotherapeutics commonly used as an adjuvant or neoadjuvant regimen 
(25). The mechanism of action is similar to that of platinum-based chemotherapeutic agents in 
targeting the DNA and preventing DNA replication (28). These chemotherapeutic agents may 
initially elicit responses but often lead to toxicities and recurrences – the two main challenges in 
treating TNBC patients, which is described more extensively in Section 1.1.3. 
 
1.1.2 Ongoing trials on targeted therapies 
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TNBC patients often do not fully respond to standard-of-care chemotherapy and/or 
surgery, resulting in poor overall survival; moreover, unlike other cancer types, there is no 
clinically approved targeted therapy as an alternative. Therefore, many studies have identified 
potential targets to improve the therapeutic outcome of TNBC patients (29). Here, I briefly 
summarize notable targets that are being tested in both pre-clinical and clinical settings.  
 
Poly-ADP ribose polymerase (PARP) has gained interest as a promising target especially for 
treating TNBC with BRCA mutation (30). PARP, like BRCA1/2, is involved in DNA repair, which 
protects cancer cells from DNA damage induced by increased genomic instability (31, 32). 
Thus, inhibiting PARP in cancer cells harboring BRCA1/2 mutations leads to even more 
susceptibility to DNA damage and cell death (33, 34). In fact, the PARP inhibitor Olaparib was 
approved by the FDA to treat a subset of TNBC patients (10-20%) that harbor genetic mutations 
in BRCA1/2 (35). Other promising PARP inhibitors such as iniparib and olaparib have resulted 
in a modest increase in progression-free survival in a Phase II/III clinical trial (32).  
 
Receptor tyrosine kinase (RTK), upstream effectors of various oncogenic pathways, are 
often elevated in TNBC (15). For instance, HER1 or EGFR family of RTKs is commonly 
overexpressed in basal-like TNBC and is correlated with poor overall survival (36). However, 
agents that target EGFR, such as cetuximab, gefitinib, and erlotinib, showed limited efficacy in 
clinical settings (37-39) (Abstract P1-11-07, SABCS). PDGF-R and VEGF-R are also targetable 
RTKs, as their ligands are highly expressed in tumor over normal stroma cells (40, 41). Blocking 
either of these receptors or the ligands appears to block angiogenesis and metastasis in 
patients (42-44). 
 
Highly oncogenic PI3K-AKT and MEK-ERK pathways that signal proliferation and 
survival are commonly overexpressed in TNBC and have long been deemed as viable targets 
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not only in TNBC but in various other cancer types (15, 45). AZD-8186, a PI3K inhibitor is being 
tested for TNBC patients (NCT01884285). The MEK inhibitor, trametinib, as a single agent in 
preclinical studies, has shown promise in breast cancer cells (46), but has not effectively 
translated into an efficacious clinical therapy. Duncan et al. showed that a possible reason for 
this failure is due to the development of resistance via kinome reprogramming (47). For 
instance, PI3K-AKT and MEK-ERK signaling pathways are interconnected and may 
compensate for each other (45, 48), which provides the rationale to test dual inhibition as an 
effective, durable therapy (NCT01964924). 
 
Immunotherapy using immune checkpoint inhibitors has been the most recent 
breakthrough in cancer treatment, especially in late stage melanoma. However, the clinical 
investigation of immunotherapy in TNBC is still inconclusive (49). There is an implication that 
the immunomodulatory (IM) subtype of TNBC with a high number of tumor infiltrating 
lymphocytes and expression of antigens (e.g. PD-1, MAGE-A, and CTLA-4) is a likely candidate 
for immunotherapy. Pembrolizumab, a PD-1 targeting antibody approved by the FDA to treat 
advanced melanoma, non-small cell lung cancer, and cervical cancer, is currently being tested 
for TNBC patients (NCT01848834; NCT02954874). 
 
1.1.3 Overcoming challenges in toxicity and recurrence with combination therapies 
	
As of 2019, there are no targeted therapies approved for TNBC patients and 
chemotherapy, radiation and/or surgery remain as the standard-of-care. Although patients may 
initially respond to chemotherapy, they often suffer from toxicity and acquired resistance, 
resulting in cancer recurrence (6, 7, 50). Common signs of toxicities caused by chemotherapy 
include immune suppression, cardiotoxicity, neuropathy, anaphylactic shock, fatigue, and 
vomiting (American Cancer Society). Such increased risks of toxicity often force the clinician to 
lower the dosage at the cost of maximal efficacy. The difficulty in determining optimal dosages 
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within a therapeutic window and increased risk for recurrence contribute to decreased efficacy 
at 5 years post-diagnosis (50). Furthermore, distant recurrence due to metastasis was reported 
to be higher in TNBC than in other breast cancer subtypes (7). As of now, the standard of care 
is not a viable long-term treatment option for TNBC patients, as they continue to suffer from 
poor overall survival outcomes. 
 
To overcome the limitations of standard of care, studies have investigated combination 
therapies involving chemotherapy and targeted agents. Combining lower dosages of 
chemotherapeutic agents has been tested for increased efficacy while lowering toxicity (51). For 
instance, addition of carboplatin to anthracycline and taxane resulted in a modest increase in 
theresponse rate, but with a significant portion of patients still experiencing adverse events due 
to toxicity (52). Another study that investigated the combination of cisplatin, epirubicin, and 
paclitaxel reported a significant response rate with low recurrence, but with a high incidence rate 
of neuropathy (53).  
 
There are many ongoing clinical trials involving combinations of chemotherapeutic and 
targeted agents to tackle unresolved challenges surrounding toxicity and recurrence. Inhibitors 
of PARP, growth factors (EGF and VEGF), and PI3K-AKT and MEK-ERK pathways are being 
tested in combinations as summarized in Table 1-1. In some studies, responses depended on 
the status of BRAC1/2 mutation or activation of the target protein such as EGFR, VEGF, AKT, 
or ERK (54-57). For instance, the new generation AKT inhibitor, ipatasertib, was tested either 
alone or in combination with paclitaxel and showed improved efficacy in patients with activated 
PI3K-AKT;however, there was no significant improvement in toxicity (58). Overall, targeted 
agents have been found to still be susceptible to resistance, leading to poor overall outcomes 
(59). Even though targeted approaches have shown promise in subsets of TNBC patients, 
toxicity and recurrence remain unresolved.  
7 
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Table 1-1: Ongoing clinical trials testing targeted agents plus chemotherapy 





SAE: Severe adverse event 
AE: Adverse event 
oRR: Overall response rate = partial response + complete response 
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1.2 CIB1 is a unique target  
 
Calcium and integrin binding protein (CIB1), a small 22-kDa intracellular protein, was 
first discovered by the Parise lab in 1997 as a novel binding partner of the integrin αIIbβ3 
cytoplasmic tail in platelets. Since then, studies led by the Parise group have discovered that 
not only does CIB1 regulate αIIbβ3 integrin in platelet precursors called megakaryocytes, but it 
also regulates kinase signaling associated with a wide spectrum of fundamental cellular 
processes including cell adhesion, cell growth, proliferation and intracellular trafficking (60-63).  
 
Structural studies showed that CIB1 contains a hydrophobic pocket that allows it to bind 
and regulate kinases (62). As an example, CIB1 was previously shown to bind and catalytically 
activate p21-activated kinase 1 (PAK1) (61). PAK1 can activate Raf and MEK, thereby 
activating ERK of the well-known Ras-Raf-MEK-ERK signaling cascade (64, 65). This signaling 
cascade is important for a diverse array of cellular processes such as cell survival, proliferation, 
differentiation, and angiogenesis (45). In addition to PAK1, CIB1 regulates the activation of AKT 
and ERK (63, 66), but by mechanisms that are not well defined, for cancer cell survival. 
Separate studies have identified other kinases that are regulated by CIB1 including EphrinA2, 
DNA-protein kinase, and apoptosis signal-regulating kinase 1, which are involved in 
macropinocytosis, DNA repair, and apoptosis, respectively (67-69). Collectively, these studies 
suggest that CIB1 is an important regulator of kinase signaling cascades during many different 
cellular processes.  
 
Interestingly, CIB1 may be a non-oncogene addiction (NOA) target due to the findings 
that CIB1 depletion causes significant cancer cell death while sparing normal cells (66). NOA 
targets often support various types of cellular stresses due to aberrant DNA replication, 
transcription, and oxidative metabolism (70). Such NOA-dependent stress pathways are more 
10 
essential for tumor cell survival rather than normal cells; therefore, loss of NOA targets such 
heat shock factor-1, much like CIB1 depletion, results in tumor cell death while sparing normal 
cells (66, 71). Further studies will be necessary to support CIB1 as a NOA target, but it is clear 
that CIB1 is a unique protein that plays diverse roles and can serve as a target for safe and 
effective therapeutic treatments. 
 
1.2.1 CIB1 supports PI3K-AKT and MEK-ERK oncogenic pathways 
	
Leisner et al and Black et al established CIB1 as a viable target for its role in supporting 
PI3K-AKT and MEK-ERK oncogenic pathways commonly activated in TNBC (63, 66). Depleting 
CIB1 via RNA interference caused concurrent inhibition of both AKT and ERK activation, 
leading to TNBC-selective cell death (66). Interestingly, TNBC cells with functional PTEN, thus 
low AKT activity were insensitive to CIB1 depletion (66). This potentially explains why normal 
breast epithelial cells with functional PTEN are unaffected by CIB1 depletion. 
 
There is no evidence that CIB1 directly regulates AKT and ERK pathways, suggesting 
that there may be additional signaling pathways that bridge CIB1 to these oncogenic pathways. 
To further understand CIB1 signaling cascades, phospho-proteomic analysis was performed in 
collaboration with the Xian Chen lab. Our goal was to uncover any additional CIB1-dependent 
signaling pathways that regulate AKT/ERK signaling and sensitivity to CIB1 depletion. The 
results from this collaboration are discussed further in Chapter 3. 
 
1.2.2 CIB1-targeted combination treatments 
	
As described in 1.2.1, CIB1 is a viable target due to its role in supporting AKT/ERK 
pathway signaling for TNBC cell survival (63). Since CIB1 depletion leads to significant TNBC 
cell death (63, 66), we the investigated whether combining CIB1 depletion with commonly used 
chemotherapeutics enhances cell death. We chose cisplatin, PARP inhibitor (ABT-888), 5-
11 
fluorouracil (5-FU), and docetaxel, commonly used agents in TNBC, to combine with CIB1 
depletion. These treatments were tested in MDA-MB-436 cells derived from a metastatic TNBC 
patient. The results in Figure 1-1 showed enhanced cell death in response to CIB1 depletion 
combined with cisplatin and docetaxel. Because these MDA-MB-436 cells were more sensitive 
to docetael (EC50 = 17 nM) than cisplatin (EC50 = 4 uM), subsequent studies focused on 




Figure 1-1. Chemotherapeutic agents cisplatin, docetaxel, 5-FU or PARP inhibitor ABT-
888 were combined with CIB1 depletion. CIB1 depletion combined with cisplatin (2 uM), 
docetaxel (35 nM), 5-FU (2 uM), or ABT-888 (30 uM) in MDA-436 TNBC cells was tested. Cells 
were infected with control or CIB1 shRNA for 2 days before addition of vehicle (water or DMSO) 
or the indicated concentrations of drugs for 48h. Percent cell death was quantified via a trypan 
blue exclusion from both adherent and floating cell populations. Data represent means +/- SD  






1.3 Importance of investigating cell death mechanisms 
 
Several clinical trials testing new combinations of chemotherapeutic and targeted agents 
resulted in low efficacy, despite promising results in pre-clinical studies (37-39, 43, 44, 72, 73). 
One potential reason for the inability of these pre-clinical studies to accurately predict clinical 
therapeutic efficacy may be due to inadequate quantification of cell death or a lack of 
understanding of the cell death mechanisms involved (74-80). My analysis of those failed 
preclinical studies revealed that they often focused on inhibiting tumor growth and proliferation, 
which may not be adequate to predict improved efficacy. Instead, speculated that tumor 
eradication as measured by tumor cell death may better predict improved efficacy. In the few 
studies that do examine cell death, investigators merely tested for classical caspase-dependent 
apoptosis induced by chemotherapy (81-84). Such chemotherapy-induced apoptosis is 
commonly susceptible to resistance (50, 85), so it is essential to investigate cell death 
mechanisms beyond caspase-dependent apoptosis, which is often defective in resistant cells 
(86). We propose that cell death mechanisms should be considered when formulating new 
combination therapies, which may better predict efficacy of new drug combinations and 
overcoming drug resistance.  
 
1.3.1 Apoptotic cell death 
	
Apoptosis is a well-known process of programmed cell death that is essential for 
maintaining normal cellular homeostasis. Morphological characteristics of apoptotic cells are 
nuclear condensation, membrane blebbing, and cell shrinkage (87). The result of these 
morphological changes is the formation of small apoptotic bodies, which are quickly engulfed by 
macrophages to be degraded (87). This process is considered “clean” or relatively free of 




The term “programmed” cell death is used to describe apoptosis because it is molecularly 
regulated. The main molecular player of apoptosis is caspase, a type of protease that becomes 
activated upon cleavage (88). There are subclasses of caspases classified as either apoptosis 
initiators or executioners. Initiators, caspase-8 and caspase-9, in an inactive state are 
monomeric pro-caspases until they dimerize with adaptor proteins as a part of a signaling 
complex (88). Such dimerization activates initiator caspases via autocatalytic cleavage, which in 
turn converges to activate executioner caspases-3, -6, or -7 (88). This caspase-mediated 
apoptotic signaling can be divided into either intrinsic or extrinsic pathways (Figure 1-2). The 
intrinsic pathway is regulated by the Bcl-2 family of pro- or anti-apoptotic proteins, which are 
localized in the mitochondria. When activated, effector Bcl-2 proteins such as Bax and Bak 
promote the release of cytochrome c from the mitochondria to the cytosol, which then forms a 
complex with apoptotic protease activating factor 1 (APAF1) (87). This complex, also called the 
apoptosome, promotes caspase-9 dimerization and activation to initiate apoptosis (87, 88). In 
contrast, the extrinsic pathway is triggered by death receptors on the membrane. Upon ligand 
binding, the cytosolic domain of the death receptor recruits caspase-8 to form death inducing 
signaling complex (DISC), which facilitates dimerization and activation of caspase-8 to initiate 
apoptosis (88). In summary, caspase-9 and caspase-8 are used as markers of intrinsic 
(mitochondrial) and extrinsic (death receptor-mediated) apoptotic pathways, respectively, as 





Figure 1-2. Schematic of apoptotic signaling pathways. The intrinsic pathway is initiated by 
Bcl-2 related pro-apoptotic proteins such as Bid, Bak, Bax, and Bim which permeabilize the 
outer membrane, which then triggers the release of cytochrome c to promote caspase-9 
activation. The extrinsic pathway is via death receptors that initiate assembly of death inducing 
signaling complex (DISC), consisting of adaptor proteins (FADD or TRADD), RIPK1, and 
caspase-8. Formation of DISC promotes activation of caspase-8. Activation of Bid may crosslink 
intrinsic and extrinsic pathways. Caspase-9 and caspase-8 activation both lead to caspase-3 
activation to execute apoptosis.   
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1.3.2 Death receptors 
 
As mentioned in 1.3.1, extrinsic apoptosis is triggered by death receptors, more 
specifically tumor necrosis factor (TNF), TNF-related apoptosis-inducing ligand (TRAIL), and 
CD95 (Fas) receptors (89, 90). The TNF receptor, despite being known as a death receptor, is 
mostly involved in pro-survival signaling for inflammation (89). In contrast, TRAIL and Fas 
receptors primarily signal cell death; therefore, our lab decided to focus on investigating these 
receptors. In fact, their ligands, TRAIL and Fas, were shown to induce tumor selective cell 
death, prompting significant interest as potential cancer therapeutics (89). For our study, we 
combined these ligands with CIB1 depletion to measure enhanced cell death and test whether 
CIB1 regulates expression of TRAIL and/or Fas receptors. Our preliminary results indicated that 
depleting CIB1 up-regulates the TRAIL receptor (Fig. 1-3). The link between CIB1 and TRAIL 




Figure 1-3. CIB1 depletion plus TRAIL, not Fas ligand potentiates TNBC cell death. In pilot 
experiments, relatively high doses (50 & 100 ng/mL) of either TRAIL (n=3) or Fas ligand (n=1) 
were added to CIB1 depleted TNBC MDA-436 cells to see if there was any effect on cell death.  
Cell death was quantified as described in Fig. 1-1. Data represent means +/- SD  (*P < 0.05, 
two-tailed t-test). 
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1.3.3 Non-apoptotic cell death 
 
When examining cell death mechanisms, we propose that investigations must extend 
beyond caspase-mediated apoptosis. Since apoptosis is susceptible to resistance, inducing 
non-apoptotic cell death may be a strategy to prolong efficacy (86). A previous study 
demonstrated that induction of non-apoptotic cell death may overcome chemo-resistance (91); 
however, overall, this approach has not been sufficiently investigated pre-clinically. Therefore, a 
more complete study of cell death mechanisms including non-apoptotic cell death could 
mechanistically explain or predict the long-term efficacy of proposed treatments. 
 
A previous study by Leisner et al. demonstrated that CIB1 depletion induces non-
apoptotic cell death via accumulation of GAPDH in the nucleus (63). This mechanism of cell 
death is independent of caspase-mediated apoptotic signaling but instead is mediated via 
nitrosylation of GAPDH that allows Siah-1 binding necessary for nuclear translocation (92). To 
test whether nuclear GAPDH causes non-apoptotic cell death in another TNBC cell line (MDA-
MB-436), we measured the rescue in viability of CIB1-depleted MDA-MB-436 cells when treated 
with deprenyl, an inhibitor of GAPDH nitrosylation (93). We found that deprenyl had no effect on 
rescuing CIB1 depleted cells (Fig. 1-4), suggesting that nuclear GAPDH does not contribute to 
CIB1 depletion-induced MDA-MB-436 cell death and may occur in a cell-type specific manner. 
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 Figure 1-4 
	
Figure 1-4. Inhibition of nuclear GAPDH translocation by deprenyl does not rescue TNBC 
cells treated with CIB1 depletion alone or in combination with docetaxel. Control or CIB1-
depleted TNBC MDA-436 cells were pretreated with vehicle (DMSO) or 50 µM z-VAD-fmk (z-
VAD) for 24 h before adding 35 nM docetaxel for 48 h. Percent cell death was quantified by 


















Necroptosis is another type of non-apoptotic cell death that we considered. Cells that 
undergo necroptosis are morphologically similar to necrotic cells. The distinction is that 
necroptosis is programmed and molecularly regulated by death receptor-mediated RIPK1/3-
MLKL signaling (94). Given that CIB1 depletion or when combination with docetaxel was shown 
to activate death receptor-mediated apoptosis (Chapter 2) and that death receptor-mediated 
apoptotic and necroptotic signaling can crosstalk (95), we hypothesized that CIB1 treatments 
may induce both apoptosis and necroptosis. After probing for phosphorylated RIPK1, a marker 
of necroptosis, we concluded that neither CIB1 depletion alone nor in combination with 
docetaxel caused necroptosis (Fig. 1-5). Additionally, inhibiting the apoptotic signaling by z-VAD 
also did not facilitate the crosstalk by activating necroptotic signaling (Fig. 1-5).  
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 Figure 1-5 
	
 
Figure 1-5. CIB1 depletion in combination with docetaxel does not activate necroptotic 
signaling, a caspase-independent mechanism of cell death. Phosphorylated RIPK1, a 
marker of necroptosis, as well of total RIPK1 were probed using control or CIB1-depleted cells 
that were pretreated with vehicle (DMSO) or 50 µM z-VAD-fmk (z-VAD) for 24 h before adding 
10 nM docetaxel for 48 h. Cleaved caspase-8 was probed to assure caspase inhibition by z-




It has been shown that autophagy, another form of non-apoptotic cell death, may cause 
degradation of RIPK1 thus inhibiting necroptosis (96). Since we observed RIPK1 degradation in 
response to CIB1 depletion or in combination with docetaxel (Fig. 1-5), we asked whether this is 
due to autophagy. To answer this, we performed Western blotting to probe for LC-III, a marker 
of autophagy, but did not find any evidence of autophagy induced by CIB1 depletion or in 
combination with docetaxel or TRAIL (Fig. 1-6). A previous study showed that active caspases 
cleave key autophagy proteins such as Beclin-1 to suppress autophagy (97). Since we know 
that these treatments activate caspase-mediated apoptosis (Chapter 2), it is possible that active 





Figure 1-6. The combination of CIB1 depletion and docetaxel does not enhance 
autophagic signaling. LC-III, a marker of autophagy, was probed using lysates from control or 




Finally, a lesser-known non-apoptotic cell death mechanism, paraptosis, was 
investigated since we observed morphological changes such as swelling and intracellular 
vesicle formation known to be observed in paraptotic cells (98-100). Molecularly, we also found 
evidence of paraptosis by detecting decreased levels of a negative regulator of paraptosis, 
ALG-2-interacting protein X (Alix-1) (100), in response to both CIB1 combination treatments 
(Fig. 2-9 and 2-10). A more detailed description of paraptosis and how this mode of cell death 




Chapter 2: CIB1 depletion with docetaxel or TRAIL enhances  





Approximately 15-20% of all breast cancer deaths in the U.S. occur in patients 
diagnosed with triple-negative breast cancer (TNBC), a subtype defined by a lack of the 
estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 [ref. 
(51)]. Due to lack of these targetable cell surface receptors, radiation, surgery, and 
chemotherapy remain the current standard of care (51, 101). While a subset of TNBC patients 
respond initially to chemotherapy, they often suffer from toxicity and acquired resistance, 
resulting in cancer recurrence and metastasis (7, 50, 101). Therefore, there is a critical need for 
efficacious therapies that limit toxicity and overcome resistance for TNBC patients.    
  
Recent efforts to improve clinical efficacy of chemotherapies have shifted towards 
combining them with targeted approaches to lower effective chemotherapeutic doses while 
maintaining therapeutic response (51, 101). For instance, in clinical trials that targeted the 
epidermal growth factor receptor (EGFR), which is commonly upregulated/activated in TNBC, 
there was no improvement in chemotherapeutic efficacy (37-39). Moreover, while ongoing 
clinical trials are testing PI3K-AKT and MEK-ERK signaling pathways downstream of EGFR, 




Our lab previously found that calcium and integrin-binding protein 1 (CIB1), an 
intracellular protein that regulates highly oncogenic PI3K-AKT and MEK-ERK signaling, may 
represent a viable target in TNBC (63, 66). We showed that CIB1 depletion simultaneously 
inhibits AKT and ERK activation and induces significant cell death in approximately 70% of 
TNBC cell lines tested and in an in vivo xenograft model (66). Common to TNBC cell lines that 
are sensitive to CIB1 depletion is elevated AKT activation. Thus, CIB1 depletion does not cause 
cell death in TNBC and normal cell lines that exhibit low basal AKT activity (66). Here, we 
evaluated cell death in TNBC versus normal breast epithelial cell lines using novel combination 
treatments involving CIB1 depletion with and without the commonly used chemotherapeutic 
docetaxel. We found that CIB1 depletion enhanced docetaxel-induced cell death selectively in 
TNBC over normal cells largely via a death receptor-mediated, as opposed to mitochondrial-
mediated apoptosis.  
 
TNF-related apoptosis-inducing ligand (TRAIL), a death receptor ligand, was once 
thought to be a promising anti-cancer agent because of its selectivity for killing tumor but not 
normal cells; however, it was not pursued due to innate or acquired resistance driven by 
dysfunctional TRAIL receptors (102, 103). Interestingly, there is a growing interest in combining 
chemotherapeutic drugs or targeted approaches with TRAIL to overcome this resistance (104-
106). Here we find that CIB1 depletion in combination with the death receptor ligand TRAIL 
potentiates TNBC-selective cell death, likely due to the upregulation of TRAIL receptor-2 
(TRAIL-R2/DR5) in CIB1-depleted TNBC cells. Thus, TRAIL in combination with CIB1 depletion 
may represent a novel mechanism to sensitize TRAIL-resistant TNBC cells.    
  
Chemotherapy not only causes toxicity, but also often leads to cancer recurrence (7). 
Since recurrence driven by drug resistance is often associated with dysfunctional apoptotic 
mechanisms (86), one approach to circumvent resistance is to induce non-apoptotic cell death 
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(50, 107). Here, we identified paraptosis as a likely non-apoptotic mode of cell death induced by 
CIB1 depletion, due to the observed cellular swelling and intracellular vacuolization that are 
morphological hallmarks of paraptosis (99, 100). Currently, there are no well-defined molecular 
mechanisms known to regulate paraptosis. However, the intracellular protein ALG-2-interacting 
protein X (Alix) has been shown to inhibit paraptosis by preventing cytoplasmic vacuolization, 
potentially by regulating endosomal sorting and fusion with other organelles (100, 108). 
Separate studies showed that known inducers of paraptosis such as withaferin A and reactive 
oxygen species decrease the expression of Alix in breast cancer cells (99, 109). Therefore, loss 
of Alix expression is considered a molecular marker of paraptosis (98-100, 109). In addition to 
dowregulation of Alix, insulin-like growth factor I receptor (IGF-1R) tyrosine kinase and JNK 
activity were found to induce paraptosis (100). Here we report that CIB1 depletion alone or in 
combination with docetaxel/TRAIL not only restores apoptotic signaling but also induces 
paraptosis in docetaxel-resistant TNBC cells. Combination therapies involving CIB1 targeting 
could therefore provide safe and durable strategies for treatment of TNBC and potentially other 
cancers.  
 
2.2 Materials and Methods 
2.2.1 Cell lines 
	
The human triple-negative breast cancer cell lines (MDA-MB-436 [Perou Lab, UNC], 
MDA-MB-468 [UNC Lineberger Tissue Culture Facility], and MDA-MB-231 [Otey Lab, UNC) 
were cultured in Dulbecco’s modified eagle medium (DMEM, Gibco) supplemented with 10% 
fetal bovine serum (Gemini) and 1% MEM non-essential amino acids (Gibco), with the addition 
of 10 ug/mL insulin for MDA-MB-436 cells. The human normal breast epithelial cell line (ME16C, 
Perou lab) was cultured in MEBM (Lonza). All cells were maintained at 37°C in a humidified 
atmosphere of 5% CO2.  
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2.2.2 Generation of docetaxel-resistant MDA-MB-436 TNBC cell line 
	
Docetaxel-resistant MDA-MB-436 cells (MDA-436-DCXR) were established by culturing 
in growth media supplemented with increasing concentrations of docetaxel (5 nM to 50 nM) over 
a 9-month period. Cells at approximately 40-50% confluency were incubated with a selected 
concentration for 48 h followed by recovery in drug-free growth media. The concentration of 
docetaxel was incrementally increased until the cells were resistant, at a final concentration of 
50 nM docetaxel (MDA-436-DCXR). Parental MDA-MB-436 cells (MDA-436-PR) were cultured 




Docetaxel (Tocris), recombinant TRAIL (PeproTech), z-VAD-fmk (Enzo Life Sciences), 
TRAIL-R2 (DR5) neutralizing antibody (R&D system), and human control IgG (Jackson Immuno 
Research) were used to treat the cell lines.  
 
2.2.4 CIB1 targeting via RNA interference in the absence and presence of docetaxel or TRAIL 
	
Construction of control and CIB1 shRNA lentiviral plasmids has been described 
previously (63, 66). Two different CIB1 targeting sequences (shCIB1-1 and shCIB1-2) were 
used to validate shRNA-induced CIB1 depletion. To knock down CIB1, cells of interest at ~30% 
confluence were infected with lentiviral shRNA containing 6 µg/mL polybrene (Sigma) for 16-18 
h followed by replacement with fresh growth media. After 24 h, the shRNA-infected cells were 
treated with vehicle, docetaxel, or TRAIL for an additional 48 h. Treated cells were then 
harvested 4 days post-infection, during which time transduction efficiency exceeds 90% as 
determined by GFP fluorescence.  
 
2.2.5 Trypan blue exclusion assay  
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Cell death was determined by trypan blue exclusion using automated fluorescently 
activated cell sorting (FACS) counting. Aliquots of 10 ul of both adherent and floating cell 
populations were collected and stained with 0.004% trypan blue (1:10 dilution). Stained dead 
cells were selected and counted using the Per-CP (APC) channel (110). Quantification of total 
live and dead cell populations was determined using an Accuri C6 Flow Cytometer (BD 
Biosciences) and data are presented as percent cell death.  
 
2.2.6 TRAIL-R1 and -R2 fluorescence detection  
	
To detect surface expression of TRAIL-R1 and –R2, 2 x 105 cells were detached using 2 
mM EDTA, washed in PBS, and resuspended in PBS (0.1 % BSA) containing antibodies for 
TRAIL-R1/DR4, TRAIL-R2/DR5 (eBiosciences) or IgG control. AlexaFluor 647 (Invitrogen) 
secondary antibody was used to detect the levels of TRAIL-R1/2, and mean fluorescence 
intensity was measured via Accuri C6 Flow Cytometer. 
 
2.2.7 Western blotting 
	
Cells were harvested and lysed with buffer containing 10 mM CHAPS as previously 
described (66). Equal amounts of protein based on total cell number were separated by SDS-
PAGE, transferred to PVDF membrane, and incubated with primary antibodies overnight at 4oC. 
Secondary HRP-conjugated antibodies against rabbit, mouse, and chicken were then used to 
visualize the immunoblots via enhanced chemiluminescence (ECL2, Pierce). The following 
antibodies were used in this study: PARP, GAPDH, cleaved caspase-8, caspase-8, cleaved 
caspase-9, caspase-9, TRAIL-1/DR4, TRAIL-R2/DR5, IGF-1R, phospho-JNK, and total JNK 
(Cell Signaling), CIB1 [chicken polyclonal antibody, (63)], vinculin (Sigma), Alix (Biolegend). 
 
2.2.8 Mitochondrial membrane potential detection 
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To detect changes in mitochondrial membrane potential, cells were stained with JC-1 
(Thermofisher), a cationic dye that accumulates in the mitochondria. Cells (1 x 106) were 
dissociated and incubated in PBS containing JC-1 (5 µM) for 30 min at 37 oC. JC-1 accumulates 
in functional mitochondria to form aggregates that fluoresce red. In dysfunctional mitochondria 
with decreased membrane potential, JC-1 will instead remain as monomers that fluoresce 
green. After washing with PBS, the emission of JC-1 fluorescence was analyzed using an 
Accuri C6 Flow Cytometer and associated software (BD Biosciences). Therefore, calculation of 
red:green JC-1 fluorescence ratio was used as the surrogate for changes in mitochondrial 
membrane potential.  
 
2.2.9 Microscopy imaging 
	
To assess morphological changes induced by CIB1 depletion in the absence and 
presence of docetaxel or TRAIL, cells were imaged in 6-well plates at the conclusion of each 
experiment. Differential interference contrast (DIC) images were captured using a Nikon TE300 




The statistically significant differences were determined using either a one-way ANOVA 
or student’s two-tailed t-test. More details on p-values are indicated in the figure legends. 
2.3 RESULTS 
	
2.3.1 CIB1 depletion selectively enhances docetaxel-induced TNBC cell death  
	
We previously reported that CIB1 depletion leads to TNBC cell death while sparing 
normal cells (66), suggesting that CIB1 may be a viable, safe target. To address the need to 
enhance tumor cell death and maintain tolerability by normal cells, we tested the targeting of 
CIB1 via RNA interference in combination with the commonly used chemotherapeutic agent, 
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docetaxel, in both TNBC and a normal breast epithelial cell line. Two different CIB1 shRNA 
sequences (shCIB1-1 and shCIB1-2) were used to validate CIB1 depletion (Fig. 2-1A). CIB1 
depletion-induced cell death quantification, cell death signaling, and cellular morphology were 
also validated using both shRNA sequences (Fig. 2-1B-H) and Western blots were quantified in 
Appendix A. Since similar results were observed with both shRNA sequences, we chose CIB1 





Figure 2-1: Validation of CIB1 depletion alone or in combination with docetaxel or TRAIL. 
MDA-436 TNBC cells were infected with either control or two different lentiviral CIB1 shRNA 
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sequences (FG12 [1] and PLKO [2]). a) Western blot results followed by quantification via 
densitometry show similar CIB1 knockdown and TRAIL-R2 upregulation in MDA-436 cells 
infected with either CIB1 shRNA-1 or -2 for 96 h. Two days-post infection, cells were treated 
with vehicle control or, b) docetaxel (1 [n=5] and 2 [n=3]), or c) TRAIL (1 [n=3] and 2 [n=3]) for 
48 h. Percent cell death was quantified via trypan blue exclusion assay and is shown as means 
+/- SD. Next, we examined death receptor-mediated apoptotic and paraptotic signaling induced 
by the combination treatment using CIB1 shRNA-1 or -2. Representative Western blot showing 
PARP, cleaved caspase-9, cleaved caspase-8, Alix, CIB1, and GAPDH in shControl (shCTRL) 
or shCIB1 (1 and 2) infected cells in combination with d) docetaxel (1 [n=5] and 2 [n=3]) or e) 
TRAIL (1 [n=3] and 2 [n=3]). FACS analysis of f) TRAIL-R1 and g) -R2 cell surface expression 
in CIB1-depleted MDA-436 cells in relative to control cells at 2, 3, or 4 days post infection. Data 
represent means +/- SD (n=3). h) Representative DIC images (20x) of shControl (shCTRL), 
shCIB1-1, or shCIB1-2 MDA-436 TNBC cells. Insets show characteristic paraptotic morphology 
in CIB1-depleted cells (shCIB1) relative to control (shCTRL). **Please note that quantifications 
of cell death (Supp Fig. S1B and S1D) and TRAIL-1/2 levels (Supp Fig S1F and S1G) using 
shCIB1-1 were taken from Figures 1-4 solely to show side-by-side comparisons with shCIB1-2.   
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To test whether the combination of CIB1 depletion and docetaxel for enhances cell 
death, we selected three different TNBC cell lines based on their sensitivity to CIB1 depletion – 
MDA-MB-436 (sensitive, Fig. 2-2A), MDA-MB-468 (sensitive, Fig. 2-2B), and MDA-MB-231 
(insensitive, Fig. 2-2C) (66). Dosages of docetaxel that caused 30-50% TNBC cell death were 
chosen to be combined with CIB1 depletion (Fig. 2-2). We found that CIB1 depletion enhanced 
docetaxel-induced cell death more effectively in CIB1 depletion-sensitive (Fig. 2-2A and 2-2B) 
versus insensitive cells (Fig. 2-2C). The enhanced TNBC MDA-MB-436 cell death was 
indistinguishable with either shCIB1-1 or -2 alone or combined with docetaxel (Fig. 2-1B). In 
contrast, CIB1 depletion alone or in combination with docetaxel did not significantly increase cell 
death in normal breast epithelial ME16C cells (Fig. 2-2D), suggesting that CIB1 targeting may 
improve chemotherapeutic efficacy by tumor-selective killing. 
 
To elucidate the mechanism underlying the enhanced TNBC cell death induced by CIB1 
depletion plus docetaxel (Fig. 2-2A-C), we analyzed cell lysates for cleaved PARP, a marker of 
apoptosis. In agreement with the observed enhanced cell death, the combined treatment-
induced PARP cleavage was only observed in TNBC (Fig. 2-2A-C) but not normal breast 
epithelial ME16C cells (Fig. 2-2D). CIB1 knockdown was confirmed by Western blotting (Fig. 2-
2A-D). Collectively, our results indicate that the novel combination of CIB1 depletion and 
docetaxel selectively enhances TNBC cell death via increased apoptotic signaling.  
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Figure 2-2. CIB1 depletion in combination with docetaxel enhances cell death and 
increases caspase activation in TNBC but not normal ME16C cells. Combination of CIB1 
depletion with docetaxel in both TNBC and normal cells was tested. Cells were infected with 
control or CIB1 shRNA for 2 days before addition of vehicle (DMSO) or the indicated 
concentrations of docetaxel for 48 h. Percent cell death in a) MDA-436 TNBC (n=5), b) MDA-
468 TNBC (n=3), c) MDA-231 TNBC (n=3), and d) ME16C normal breast epithelial cells (n=4) 
was quantified via a trypan blue exclusion assay from both adherent and floating cell 
populations. Lysates prepared from cells in a)-d) [n=5; 3; 3; 4, respectively] were analyzed by 
Western blotting with the indicated antibodies (lower panels). Data represent means +/- SD  (*P 
< 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001, ANOVA). 
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2.3.2 CIB1 depletion with docetaxel induces death receptor-mediated apoptosis 
	
To further understand the apoptotic signaling mechanisms induced by CIB1 depletion in 
combination with docetaxel, we asked whether death receptor-mediated or mitochondrial 
apoptosis, which are initiated by caspase-8 and caspase-9, respectively, contributed to the 
observed cell death. We detected degradation of inactive pro-caspase-8 and the appearance of 
active or cleaved caspase-8, but not caspase-9, in CIB1-depleted cells treated with docetaxel 
(Fig. 2-3A and 2-1C). In contrast, we detected minimal caspase-8 activity in CIB1-depleted cells 
alone (Fig. 2-3A and 2-1C), suggesting that CIB1 depletion may prime TNBC cells for death 
receptor-mediated apoptosis. Comparable effects on apoptotic signaling induced by CIB1 
depletion alone or with docetaxel was also observed using CIB1 shRNA-2 (Fig. 2-1C). We 
additionally probed for caspase-10, a controversial marker of death receptor-mediated 
apoptosis (111), and found no further caspase-10 activation upon combination treatments (data 
not shown). Caspase-3, a downstream substrate of caspase-8, was also activated by the 
combination treatment (Fig. 2-3A). In contrast, we did not observe caspase activation in control 
or CIB1-depleted ME16C normal breast epithelial cells with or without docetaxel (Fig. 2-3B). 
CIB1 depletion in combination with docetaxel also selectively activated caspase-8 in two 
additional TNBC cell lines, MDA-468 (Fig. 2-4A) and MDA-231 cells (Fig. 2-4B). Collectively, 
these results suggest that death receptor-mediated apoptotic signaling contributes 
mechanistically to enhanced cell death induced by the combination of CIB1 depletion and 




Figure 2-3. CIB1 depletion combined with docetaxel enhances death receptor-mediated 
apoptotic signaling. Docetaxel-induced caspase-8 and -3 activation is enhanced in CIB1-
depleted MDA-436 but not normal ME16C cells. Control or CIB1-depleted a) MDA-436 TNBC 
(n=5) and b) ME16C normal breast epithelial cells (n=4) were treated with docetaxel as in 
Figure 1. Lysates prepared from each cell line were probed for pro-caspase-8, cleaved 












Figure 2-4: CIB1 depletion plus docetaxel activates death receptor-mediated apoptosis in 
other TNBC cells. Caspase-8 activation is observed in TNBC cell lines treated with the 
combination of CIB1 depletion and the indicated concentrations of docetaxel. Control and CIB1-
depleted a) MDA-468 (n=3) and b) MDA-231 (n=3) cells were treated with either vehicle 
(DMSO) or docetaxel as in Figure 2-1B. Representative Western blot showing cleaved caspase-
8 and GAPDH (lower panel, n=3). 
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2.3.3 CIB1 depletion sensitizes TNBC, but not normal cells to TRAIL 
	
Since CIB1 depletion enhances docetaxel-induced TNBC cell death via increased death 
receptor signaling, we investigated the link between CIB1 depletion and two cytotoxic death 
receptors, TRAIL (TRAIL-R) and Fas. Treatment of CIB1-depleted MDA-436 cells with Fas 
ligand had no effect on cell death or caspase-8 activation (data not shown), and therefore was 
not pursued further. However, treatment with TRAIL caused a dose-dependent increase in 
PARP cleavage (Fig. 2-5A). Notably, CIB1 depletion sensitized MDA-436 cells to TRAIL, 
resulting in a synergistic increase in cell death (Fig. 2-5A and 2-1D). In contrast, CIB1 depletion 
plus TRAIL failed to induce PARP cleavage and cell death in normal ME16C cells (Fig. 2-5B), 
indicating that this combination is highly selective in killing TNBC while sparing normal cells. 
Further, the enhanced cell death correlated with active or cleaved caspase-3 and caspase-8, 
but not caspase-9, in CIB1 shRNA-1 and shRNA-2 depleted MDA-436 TNBC cells (Fig. 2-5C 
and 2-1E) not ME16C cells (Fig. 2-5D). Caspase-8 activation was also confirmed by the 
corresponding degradation of inactive pro-caspase-8 (Fig. 2-5C). Although we did not detect 
caspase-9 activation (Fig. 2-5C), staining with the mitochondrial dye JC-1 revealed increased 
mitochondrial dysfunction in CIB1-depleted cells alone and in combination with both TRAIL and 
docetaxel (Fig. 2-6A). Caspase-8 can cleave the pro-apoptotic Bcl-2 member, Bid, which is an 
important mediator of mitochondrial dysfunction (112). Consistent with our JC-1 results, we 
detected increased Bid cleavage in CIB1 depleted cells treated with either docetaxel or TRAIL 




Figure 2-5. CIB1 depletion sensitizes MDA-436 TNBC but not normal ME16C cells to 
TRAIL. Combination of CIB1 depletion with TRAIL in both TNBC and normal cells was tested. 
Cells were infected with control or CIB1 shRNA for 2 days before the addition of vehicle (water) 
or the indicated concentrations of a death receptor ligand TRAIL for 48 h. Percent cell death 
quantified via trypan blue exclusion using a) MDA-436 TNBC (n=4) and b) ME16C normal 
breast epithelial cell lines (n=3). Data represent means +/- SD  (*P < 0.05, **P < 0.01, ***P < 
0.001, and ****P < 0.0001, ANOVA). CIB1 depletion plus TRAIL enhanced caspase-8 and -3 
activation. Representative Western blot for pro-caspase-8, cleaved caspase-8, pro-caspase-9, 
cleaved caspase-9, cleaved caspase-3, CIB1, and vinculin in c) MDA-436 TNBC (n=3) and d) 




Figure 2-6: CIB1 depletion plus docetaxel or TRAIL activates Bid and disrupts 
mitochondrial membrane potential. Mitochondrial apoptosis was further investigated by 
probing for a pro-apoptotic Bcl-2 related protein, Bid, and analyzing mitochondrial membrane 
potential by staining with JC-1. Control or CIB1-depleted MDA-436 cells were treated with 
docetaxel/TRAIL, followed by immunoblotting and  JC-1 staining. Lysates from combination 
treatments involving a) docetaxel (n=2) and b) TRAIL (n=2) were probed for Bid and GAPDH 
(loading control using. c) Quantification of JC-1 aggregates (red) versus monomers (green) was 
used a surrogate for mitochondrial membrane potential. Data are represented in means +/- SD 
(n=3). p-value * <0.05; ** <0.01 compared to untreated control, two tailed t-test. 
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Interestingly, we also observed a similar increase in caspase-8 activation and cell death upon 
addition of TRAIL to CIB1-depleted MDA-468 (Fig. 2-7A) but not MDA-231 TNBC cells (Fig. 2-
7B). This suggests that the cell death induced by the combination of CIB1 depletion and TRAIL, 
unlike that induced by docetaxel, is cell-type specific based on sensitivity to CIB1 depletion. 
Thus, adding TRAIL to CIB1 depletion-sensitive cells is a potent combination for inducing 




Figure 2-7: CIB1 depletion plus TRAIL increases death receptor-mediated apoptosis in a 
CIB1 depletion-sensitive TNBC cells. CIB1 depletion in combination with TRAIL induces cell 
death in CIB1-depletion sensitive but not insensitive TNBC cells. Control and CIB1-depleted a) 
MDA-468 and b) MDA-231 cells were treated with either vehicle (water) or TRAIL as in Figure 
2-1B. Percent cell death quantified as in Fig. S1 and is shown in means +/- SD (n=3) (*P < 0.05, 
**P < 0.01, ***P < 0.001, and ****P < 0.0001, ANOVA). Interestingly, increased caspase-8 
activity in response to CIB1 depletion plus TRAIL was detected in both cells. Representative 
Western blots of 3 separate experiments showing PARP, cleaved caspase-8, CIB1, and 
GAPDH expression (lower panel). 
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2.3.4 TRAIL-R2 upregulation by CIB1 depletion sensitizes TNBC cells to TRAIL 
 
Because CIB1 depletion sensitizes TNBC cells to TRAIL, we asked whether this effect 
was due to increased TRAIL-R expression. We measured cell-surface and whole cell 
expression of TRAIL-R1 (DR4) and/or -R2 (DR5) using flow cytometry and Western blotting, 
respectively. We found that TRAIL-R2, but not TRAIL-R1, was upregulated on the surface of 
CIB1-depleted versus control MDA-436 TNBC cells, starting 2 days post-infection with both 
CIB1-1 and CIB1-2 shRNA sequences (Fig. 2-8A and 2-8B; 2-1F and 2-1G). This was notable 
because TRAIL was added 2 days post-infection and coincides with acquired sensitivity to 
TRAIL. Whole cell expression levels of TRAIL-R2 also increased with CIB1 depletion starting at 
Day 2, but more significantly at Day 3 post-infection (Fig. 2-8C). Next, to confirm that TRAIL-R2 
upregulation upon CIB1 depletion was responsible for sensitizing MDA-436 cells to TRAIL, we 
blocked TRAIL-R2 function by pre-treating control or CIB1-depleted MDA-436 TNBC cells with a 
neutralizing (TRAIL-R2 Fc) antibody. Blocking TRAIL-R2 prevented the increased cell death 
induced by TRAIL in CIB1-depleted cells (Fig. 2-8D). Further, this rescue of cell viability by the 
TRAIL-R2 neutralizing antibody was also associated with decreased PARP cleavage and 
caspase-8-activation, whereas the upregulation of TRAIL-R2 by CIB1 depletion remained intact 
(Fig. 2-8E). These results indicate that CIB1 depletion-induced TRAIL-R2 upregulation 





Figure 2-8. CIB1 depletion upregulates TRAIL-R2 expression. Death receptors TRAIL-
R1/R2 levels in MDA-436 cells were measured at Days 2, 3, and 4 post-infection with either 
control or CIB1 shRNA. a) FACS analysis shows upregulation of cell surface levels of TRAIL-
R2, but not TRAIL-R1, starting at 2, 3 and 4 days post-infection (2nd and 3rd row) with CIB1 
shRNA (red) relative to control (black). b) Means +/- SD (n=3) of fluorescence intensities of 
CIB1 shRNA-infected MDA-436 cells normalized to control cells shown in a). c) Representative 
western blot (n=3) showing increased whole cell expression of TRAIL-R2, but not TRAIL-R1, in 
CIB1-depleted MDA-436 cells at 3 and 4 days post-infection with CIB1 shRNA. d) TRAIL-R2 
neutralizing antibody blocks TRAIL-induced cell death in CIB1-depleted cells. Control or CIB1-
depleted MDA-436 cells were pre-treated with either IgG control or TRAIL-R2 neutralizing 
antibody (TRAIL-R2 Fc, 1 ng/mL) for 24 h before addition of vehicle (water) or 10 ng/mL 
recombinant TRAIL ligand for 48 h (n=3). Cell death was quantified as in Figure 1 (** P < 0.01). 
e) Blocking TRAIL-R2 inhibits TRAIL-induced PARP cleavage and caspase-8 activation in CIB1-
depleted MDA-436 cells. Representative Western blot of PARP, TRAIL-R2, cleaved caspase-8, 
CIB1, and GAPDH (loading control) in treatment groups shown in d) (n=3). 
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2.3.5 CIB1 depletion plus docetaxel or TRAIL induces caspase-independent cell death 
	
To confirm apoptosis as the primary mechanism underlying the observed death of CIB1-
depleted MDA-436 TNBC cells with or without docetaxel/TRAIL, we pre-treated cells with the 
pan-caspase inhibitor, z-VAD-fmk (z-VAD). Surprisingly, we found that z-VAD partially rescued 
MDA-436 cell viability induced by CIB1 depletion in combination with either docetaxel (Fig. 2-9A) 
or TRAIL (Fig. 2-9B) despite complete inhibition of caspase-8 and caspase-3 activation (Fig. 2-
9C and 2-9D).  These results led us to investigate the contribution of caspase-independent cell 
death mechanisms. Phenotypically, we noticed that CIB1 depletion alone induced cellular 
swelling and intracellular vacuolization (Fig. 2-1H), which are characteristic of autophagic, 
necroptotic, or paraptotic modes of caspase-independent non-apoptotic cell death (100, 107, 
113). After detecting no changes in LC-III and p-RIPK1 levels, markers of autophagy (Appendix 
B) and necroptosis (Appendix C), respectively, those modes of cell death seemed less likely. 
We then assessed ALG-2-interacting protein X (Alix) protein expression levels, which correlate 
inversely with induction of paraptosis (99, 100). We detected decreased Alix expression upon 
CIB1 depletion in combination with either docetaxel (Fig. 2-9C) or TRAIL (Fig. 2-9D) (0.3 or 
0.08-fold respectively). Even with z-VAD pre-treatment, we detected decreased Alix expression 
in response to CIB1 depletion plus docetaxel or TRAIL (0.6 or 0.7-fold respectively, Fig. 5C and 
5D), suggesting paraptosis as a non-apoptotic component of cell death. Additionally, z-VAD plus 
Alix-1 overexpression did not further rescue cell viability, suggesting that Alix-1 is not the sole 
mediator of paraptosis (Appendix D). In fact, paraptosis can also be mediated by IGF-1R 
signaling and JNK activation (100) we probed for IGF-1R expression and phospho-JNK. We 
found that CIB1 depletion alone led to increased IGF-1R expression, and the combination 
treatment activated JNK signaling, further supporting the involvement of paraptosis (Figure 2-
10A). Although not a specific inhibitor of paraptosis (protein synthesis inhibitor), pre-treatment 
using cycloheximide rescued CIB1 depleted TNBC cells (Figure 2-10B). These findings suggest 





Figure 2-9. CIB1 depletion in combination with docetaxel or TRAIL induces caspase-
independent cell death. Pre-treatment using a pan-caspase inhibitor, z-VAD-fmk (z-VAD) 
helped to determine contributions of caspase-independent, non-apoptotic cell death 
mechanisms induced by the combination treatments. Control or CIB1-depleted cells were 
pretreated with vehicle (DMSO) or 50 µM z-VAD-fmk (z-VAD) for 24 h before adding a) 10 nM 
docetaxel or b) 10 ng/ml TRAIL for 48 h. The concentrations for docetaxel and TRAIL were 
chosen because we observed a sufficient increase in cell death and caspase-8 activity when 
combined with CIB1 depletion. Percent cell death was quantified as in Figure 1, represented by 
means +/- SD, * P < 0.05 (n = 3). z-VAD inhibits caspase-8 but does not affect PARP activation 
or the expression of a marker of paraptosis, Alix. Lysates prepared from control or CIB1-
depleted cells in a) and b) treated with c) docetaxel or d) TRAIL were probed with for PARP, 
cleaved caspase-8, cleaved caspase-3, Alix, CIB1, and vinculin (loading control). Western blot 





Figure 2-10. Combination of CIB1 depletion and docetaxel/TRAIL induces paraptosis. 
Paraptotic signaling was funder investigated by analyzing IGF-1R and JNK pathways. a) Control 
or CIB1 depleted MDA-436 cells were treated with either docetaxel (10 nM  & 35 nM) or TRAIL 
(5 ng/mL & 10 ng/mL) as described in Figure 1. Lysates were probed for IGF-1R, 
phosphorylated JNK, total JNK, and GAPDH (n=2). b) To determine the contribution of 
paraptotic cell death, control or CIB1-depleted MDA-436 cells were pretreated with vehicle 
(DMSO) or 5 mM of the protein synthesis inhibitor cycloheximide for 24 h before adding 30 nM 
docetaxel or 10 ng/ml TRAIL for 48 h. Percent cell death was quantified and normalized to 
control, represented by means +/- SD (n = 3).  
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2.3.6 Docetaxel-resistant TNBC cells remain sensitive to CIB1 depletion alone or in combination 
with docetaxel or TRAIL 
	
Defective apoptosis is one mechanism of resistance and a major obstacle for effective 
chemotherapy (86). Therefore, we asked whether CIB1 depletion overcomes resistance by 
restoring apoptosis (Fig. 2-11). To answer this question, we generated docetaxel-resistant 
MDA-MB-436 cells (MDA-436-DCXR). Resistance was confirmed by comparing the EC50 of 
docetaxel in parental (MDA-436-PR; 3 nM) versus resistant (MDA-436-DCXR; 219 nM) cells (Fig. 
2-12A). CIB1 depletion alone or with docetaxel (Fig. 2-11A) or TRAIL (Fig. 2-11B) induced 
significant cell death in docetaxel-resistant MDA-436-DCXR cells. Western blotting analysis 
showed that although docetaxel-induced caspase-8 activity is compromised in MDA-436-DCXR 
resistant cells, CIB1 depletion alone and in combination with docetaxel restored caspase-8 
activity in these cells (Fig. 2-11C). Contrary to previous findings, caspase-8 activity was not 
detected in CIB1-depleted MDA-436-PR parental cells with or without docetaxel/TRAIL (Fig. 2-
11C). This may be due to alterations in caspase activities (114) resulting from extended 
culturing of MDA-436–PR cells during the process of establishing  MDA-436-DCXR cells  (> 9 
months with  >60 passages). Unexpectedly, CIB1 depletion plus TRAIL caused nearly complete 
death of MDA-436-DCXR cells (Fig. 2-11B), which may explain an apparent lack of GAPDH 
expression (Fig. 6C) due to the lysates being composed of mostly floating dead cells. The 
nearly complete MDA-436-DCXR cell death correlated with a more profound caspase-8 
activation (Fig. 2-11C). This further amplification of caspase-8 activity could be due to increased 
cell surface expression of both TRAIL-R1 and –R2 on CIB1-depleted MDA-436-DCXR cells as 
opposed to only TRAIL-R2 in CIB1-depleted MDA-436-PR cells (Fig. 2-12B and 2-12C). Whole 
cell expression levels of TRAIL-R2 increased with CIB1 depletion in MDA-436-DCXR cells (Fig. 
2-12D). These results suggest that CIB1 depletion alone and in combination with either 
docetaxel or TRAIL has the potential to overcome chemo-resistance.   
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Since another strategy to circumvent chemo-resistance is to induce non-apoptotic, 
caspase-independent cell death (107), we asked whether paraptosis also occurs in docetaxel-
resistant cells. Indeed, we found that either CIB1 depletion alone or in combination with 
docetaxel or TRAIL decreased Alix levels in MDA-436-DCXR cells (Fig. 2-11C). Moreover, 
paraptotic morphologies such as swelling and intracellular vacuole formation were observed in 
resistant cells in response to CIB1 depletion alone or in combination with docetaxel/TRAIL (Fig. 
2-11D). The morphology of CIB1-depleted cells mimicked the effects of docetaxel (Fig. 2-11D), 
a parental compound to paclitaxel, which is known to cause paraptotic morphology at high 
doses (115). Although the combination treatments did not activate the JNK pathway, CIB1 
depletion alone led to upregulation of IGF-1R, an upstream effector of paraptosis, in docetaxel-
resistant TNBC cells similar to that observed in parental cells (Figure 2-12E). These results 
collectively show that the combination treatments both restore apoptosis and induce paraptosis 





Figure 2-11. Docetaxel resistant MDA-436 cells are sensitive to CIB1 depletion alone and 
in combination with docetaxel or TRAIL. To determine whether chemo-resistance is 
overcome by the combination treatments, cell death and its mechanism were analyzed. Control 
or CIB1-depleted MDA-436-PR (parental) and MDA-436-DCXR (docetaxel-resistant) cells were 
treated with either a) vehicle control (DMSO) or 10 nM docetaxel (n=3), b) or 5 ng/mL TRAIL 
ligand (n=3) for 48 h. Percent cell death shown in means +/- SD was quantified as in Figure 1. 
c) Western blots showing increased caspase-8 activation and decreased Alix expression in 
CIB1-depleted MDA-436-DCXR cells alone or in combination with docetaxel or TRAIL, 
representative of 3 individual experiments. GAPDH was used as a loading control. d) 
Representative DIC images (20x) of control or CIB1-depleted parental (MDA-436-PR) and 
MDA-436-DCXR cells treated with either vehicle or 10 nM docetaxel or 5 ng/ml. Insets show 






Figure 2-12 CIB1 depletion may upregulate TRAIL-R1/R2 and IGF-1R expression in 
docetaxel-resistant TNBC cells. CIB1 depletion potentiates TRAIL-induced cell death in 
docetaxel-resistant MDA-436 cells potentially via upregulation of both TRAIL-R1 and –R2. a) 
Dose-response of docetaxel-induced cell death in parental (MDA-436-PR) versus docetaxel-
resistant (MDA-436-DCXR) TNBC cells over 48 hr confirms resistance in MDA-436-DCXR cells. 
Cell death was quantified using trypan blue exclusion assay. Data represents means +/- SD 
(n=2). FACS analysis of cell surface expression of b) TRAIL-R1 and c) TRAIL-R2 in CIB1 
depleted (shCIB1) MDA-436-PR and MDA-436-DCXR cells normalized to IgG-stained control 
cells (shCTRL) 4 days post infection with RNA interference. Data represent means +/- SD (n=3); 
* P < 0.05; ** P < 0.01. d) Representative Western blot from 3 separate experiments showing 
TRAIL-R1, TRAIL-R2, and vinculin (loading control) expression in MDA-436-PR and MDA-436-
DCXR cells 3 and 4 days post-infection with either shControl (Ctr) or shCIB1 (CIB1). e) 
Paraptotic signaling in a chemo-resistant setting was analyzed by probing for IGF-1R, phospho-
JNK, total JNK, and Rac (loading control) in control or CIB1-depleted parental and docetaxel-
resistant TNBC cells treated with either docetaxel (10 nM) or TRAIL (5 ng/mL) for 48 h (n=2). 
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2.4 DISCUSSION  
	
The standard of care for TNBC patients, chemotherapy and/or surgery, often fails due to 
development of resistance and toxicity (7, 25). To address this need, clinical trials have 
centered on combining targeted therapies with chemotherapeutics, yet resistance and toxicity 
persist to limit the overall efficacy (38, 39, 50, 101). Our previous work indicated that CIB1 may 
be a potentially safe target due to its selectivity for killing TNBC but not normal cells when 
depleted (66). Therefore, we tested a novel combination treatment with CIB1 depletion and a 
commonly used chemotherapeutic, docetaxel to enhance TNBC-selective cell death. 
 
In this study, we focused on detecting and understanding the mechanisms of cell death 
to assess the combination of CIB1 depletion and chemotherapeutics. Many previous pre-clinical 
cell culture-based TNBC studies that combine targeted agents with chemotherapeutics have 
focused primarily on slowing cell proliferation as opposed to cell death (75, 77, 79, 80). 
Moreover, studies that have quantified cell death were often limited to studying classical 
caspase-dependent apoptosis (83, 84, 116, 117). In contrast, we investigated both apoptotic 
and non-apoptotic TNBC cell death in response to CIB1 depletion alone or in combination with 
docetaxel. In addition, we demonstrate that induction of non-apoptotic cell death is an effective 
strategy to circumvent resistance, which is often associated with dysfunctional apoptotic 
signaling (91, 107, 118). Thus, we propose that quantification of cell death in tumor versus 
normal cells may identify combinations that eradicate tumors while sparing normal cells, which 
may be a better indicator for a safer, more efficacious therapy. 
 
Initially, we found that combining CIB1 depletion with docetaxel significantly enhances 
TNBC cell death while sparing normal breast epithelial cells. The enhanced cell death correlated 
with increased death receptor-mediated (caspase-8) apoptotic signaling, selectively in TNBC 
relative to normal cells. Subsequently, we found that the combination of CIB1 depletion and the 
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death receptor ligand TRAIL is potent in selectively killing TNBC cells via increased caspase-8 
activation. While TNBC cells are inherently resistant to TRAIL alone, CIB1 depletion appears to 
sensitize these cells to TRAIL by upregulating TRAIL receptor-2. Once believed to be a safe, 
tumor-specific targeting therapy, TRAIL as a mono-therapy failed due to resistance driven by 
mutations in TRAIL receptors and dysfunctional signaling complexes at the receptor intracellular 
domain (102, 103, 119). Subsequent studies have focused on combination approaches using 
chemotherapeutics, natural compounds and targeted agents to sensitize otherwise resistant 
breast cancer cells to TRAIL by upregulating TRAIL receptors and restoring TRAIL receptors’ 
intracellular signaling complex activity (106, 120-125). In comparison, our approach of targeting 
CIB1 allowed us to use 5- to 10-fold lower concentrations of TRAIL to induce as much or greater 
cytotoxicity in cultured TNBC cells. The selectivity of TRAIL-based combination treatments for 
tumor cells is consistent between our results and the published results of other studies (106, 
123, 125). However, those studies provide limited understanding as to why normal cells are 
unaffected by TRAIL-based combination treatments. We speculate that CIB1 depletion may 
upregulate decoy receptors, which inhibit intracellular TRAIL receptor signaling and initiate pro-
survival NF-κB signaling (126, 127) (Appendix E), thereby protecting normal breast epithelial 
cells from TRAIL-induced cell death. Another mechanism may involve the internalization of 
TRAIL receptors and expression of intracellular signaling complex modulators such as c-FLIP, 
XIAP, and IAP in normal cells, to explain TNBC-selective cell death. We believe that a better 
understanding of cell death mechanisms underlying tumor selectivity versus normal cells could 
provide further rationale to test a TRAIL-based combination treatment with CIB1 targeting. 
 
The induction of non-apoptotic death could prove to be an effective therapeutic strategy 
to circumvent resistance (91, 107, 128, 129). In addition to previously identifying GAPDH 
nuclear translocation (63), we found paraptosis as another mode of non-apoptotic cell death 
associated with CIB1 depletion. To our knowledge, we are the first to report paraptosis as a 
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mechanism for overcoming chemoresistance in TNBC cells. While autophagy is another mode 
of non-apoptotic cell death that shares phenotypic characteristics similar to paraptosis, we did 
not observe activation of LC-III, a marker of autophagy. Necroptosis, like apoptosis, can be 
activated downstream of death receptors to cause a caspase-independent paraptotic-like, 
necrotic phenotype (94). However, we found no effect on the necrotic marker p-RIPK or the 
necroptosis inhibitor necrostatin-1 and therefore concluded that CIB1 depletion alone or in 
combination with either docetaxel or TRAIL does not induce necroptosis. Because pre-treatment 
with cycloheximide, a protein synthesis inhibitor, rescued CIB1 depleted TNBC cells from cell 
death, protein synthesis may be investigated to further understand non-apoptotic cell death in 
relation to CIB1. Future studies examining non-apoptotic modes of cell death associated with 




In summary, we find that targeting CIB1 in combination with docetaxel or TRAIL is 
selective in killing TNBC over normal breast epithelial cells. Also, both combinations restore 
apoptosis and induce non-apoptotic cell death to overcome resistance (Fig. 7), suggesting well-
tolerated and durable treatment options. Hence, we speculate that CIB1 as a target may provide 
new avenues for formulating effective combination therapies not only for TNBC but other 




Figure 2-13. Model of cell death mechanisms induced by CIB1 depletion alone or in 
combination with docetaxel/TRAIL. The combination of CIB1 targeting via RNA interference 
and docetaxel/TRAIL activates both apoptotic and non-apoptotic (paraptotic) signaling to induce 
TNBC-selective cell death and overcome chemo-resistance. Caspase-3/-8 activation and 




Chapter 3: Phosphoproteomic analysis reveals a new role of CIB1 in regulating  




Triple-negative breast cancer (TNBC) is often driven by hyper-activated oncogenic AKT 
and ERK pathways (15, 16). CIB1 is an attractive target for its role in concurrently regulating 
both AKT and ERK pathways (63, 66). Our lab previously demonstrated that depleting CIB1 by 
RNA interference inhibits AKT and ERK activities, leading to TNBC cell death and tumor 
shrinkage in vivo (63, 66). Additionally in Chapter 2, we showed that CIB1 depletion in 
combination with the chemotherapeutic agent, docetaxel, or the death-inducing ligand, TRAIL, 
enhances selective killing of TNBC cells. While Chapter 2 focused on investigating cell death 
mechanisms, this chapter will focus on understanding how CIB1 regulates AKT, ERK pathways 
and potentially other CIB1-dependent pathways for survival. For this study, we utilized a global 
approach via phosphoproteomics to identify new signaling players that may link CIB1 to AKT 
and ERK pathways.  
 
To perform phosphoproteomic analysis, we collaborated with the Xian Chen lab at UNC 
where they follow a modified version of EasyPhos platform (130) to digest and enrich for 
phospho-peptides in preparation of mass spectrometry analysis using an Q Exactive instrument. 
By eliminating the fractionation steps, their approach minimizes the loss of peptides while 
maximizing sensitivity and accuracy. We analyzed two TNBC cell lines differentiated by their 
sensitivity to CIB1 depletion, and AKT hyperactivity (66). For instance, CIB1 depletion-sensitive 
MDA-468 cells harbor hyperactivated AKT whereas insensitive MDA-231 cells do not. Using 
these TNBC cells, we profiled the phosphoproteomic changes in response to CIB1 depletion 
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relative to wild-type control with the goal of uncovering novel CIB1-dependent signaling players 
that are involved in AKT/ERK pathways.  
 
Interestingly, we detected phosphorylation of phosphatases such as Protein 
Phosphatase 2A (PP2A). More specifically, we identified PP2A regulatory subunit B56 epsilon 
domain (PP2A B56ε) as significantly phosphorylated in CIB1 depleted MDA-468 but not MDA-
231 cells. Since PP2A is a well-known inhibitor of both AKT and ERK signaling pathway in 
cancer (131), we hypothesized that phosphorylation of PP2A B56ε by depleting CIB1 is 
necessary to inhibit AKT/ERK pathways and promote cell death. 
 
Protein Phosphatase 2A (PP2A) is a serine/threonine phosphatase that regulates a 
broad range of cellular functions including cell survival, apoptosis, cell cycle, and DNA damage 
response (131, 132). PP2A enzymes are heterotrimers composed of subunits A, B, and C (133). 
Subunit A serves as a structural scaffold whereas subunit C contains a catalytic site that, once 
activated, triggers de-phosphorylation of various substrates (133). Subunit B is considered the 
master regulator of PP2A by determining its substrate specificity (133). This regulatory subunit 
B is classified into four different families: B55/B’, B56/B’’, PR72/B’’’, and striatin/B’’’’. B55 family 
targets broad range of proteins involved in cell cycle and cell survival whereas B56 has been 
linked to apoptotic signaling and DNA damage response (133-135). Interestingly, a cross-talk 
between B55 and B56 has been implicated in regulating cell cycle progression (136). Therefore, 
it is not surprising that subunits B55 and B56 have been reported to regulate AKT and ERK 
pathways in cancer (137-142). In contrast, PR72 and striatin subunits are not as well studied 
and their role in cancer is unclear. This prompted us to validate the phosphoproteomic results of 
PP2A and, more specifically, the B56ε subunit in relation to CIB1. Furthermore, we tested 
whether the newly discovered link between CIB1 and PP2A B56ε is essential for regulating AKT 
and ERK activities and cell viability.  
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Phosphoproteomic profiling also revealed a significant increase in phosphorylation of 
another phosphatase, SH2 Domain-Containing Inositol-5-Phosphatase (SHIP2), again in MDA-
468 but not MDA-231 cells. Like PP2A, SHIP2 is involved in regulating the AKT/ERK pathways 
(143). An activated form of SHIP2 targets PIP3 to shut off PI3K signaling downstream to AKT 
and ERK pathways (144). Many studies have identified tyrosine phosphorylation mainly at 
residues 986 and 1162 as indicators of SHIP2 activation in response to insulin or growth factors 
(145-147), leading to cell attachment and spreading (148). In contrary, our phosphoproteomic 
analysis revealed phosphorylation at serine-132 of SHIP2. Compared to other phosphorylation 
sites, serine-132 is not well-studied and its effect on SHIP2 phosphatase activity is unclear. 
Collectively, we asked whether phosphorylation of PP2A B56ε and SHIP2 by CIB1 depletion 
increases their phosphatase activities and, if so, whether CIB1 depletion-induced phosphatase 
activity of PP2A B56ε and SHIP2 is necessary to inhibit AKT/ERK pathways and TNBC cell 
viability. By answering these questions, we aimed to provide novel mechanistic explanations to 
further understand how CIB1 promotes cell survival in TNBC. 
 
3.2 Materials and Methods 
	
3.2.1 Cell lines 
	
MDA-468 and MDA-231 TNBC cells were previously engineered to stably express 
doxycycline (Dox)-inducible shRNA targeting CIB1 as described in Black et al (66). Both TNBC 
cells were cultured in Dulbecco’s modified eagle medium (DMEM, Gibco) supplemented with 
10% fetal bovine serum (Gemini) and 1% MEM non-essential amino acids (Gibco) and 
incubated at 37°C in a humidified atmosphere of 5% CO2. CIB1 knockdown was induced by 





Doxycycline (Sigma), LB-100 (Selleckchem), and AS1949490 (Tocris) were used to treat 
aforementioned TNBC cells. 
 
3.2.3 Phosphoproteomic profiling of CIB1-depleted MDA-468 and MDA-231 cells 
Approximately 4 x 106 MDA-231 and MDA-468 TNBC cells were plated without the 
addition of doxycycline as a control. As opposed to 4 x 106 MDA-231 cells, 12 x 106 MDA-468 
cells were plated for doxycycline-induced CIB1 knockdown to account for the expected loss of 
MDA-468 cell viability. After 96 h incubation, control and CIB1-depleted MDA-231 and MDA-468 
cells were harvested, washed with PBS, and frozen at -80 oC. A large number of cells were 
harvested, yielding sufficient protein concentration to perform phosphoproteomic analysis. A 
small portion of the harvested cells was lysed and probed for CIB1 to confirm CIB1 knockdown. 
 
To perform phosphoproteomic analysis, we collaborated with the Xian Chen lab. They 
processed our cells by following their modified version of EasyPhos platform (130) to enrich for 
phospho-peptides that were loaded into Q Exactive mass spectrometer for analysis. The 
parameters were set by the Chen lab to detect phospho-peptides that are less than 
approximately 15 amino acids to ensure sensitivity and accuracy of the results. 
 
3.2.4 Analysis of phosphoproteomic profiles using Ingenuity Pathway Analysis (IPA) 
	
To identify novel CIB1-dependent proteins, we used Ingenuity Pathway Analysis (IPA) 
software with parameters set to identify upregulated or downregulated sites by log2 fold change 
in CIB1 depleted versus control cells (p-value < 0.05). Using IPA, we were able to sort proteins 
by their associated signaling pathways. This bioinformatics approach helped us to more 
efficiently identify proteins involved in AKT and/or ERK pathways.  
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3.2.5 RNA interference-mediated silencing of SHIP2 
	
To silence SHIP2 in control or CIB1-depleted MDA-468 cells, we used siRNA targeting 
INPPL1 (Invitrogen INPPL1HSSA179945). The siSHIP2 was resuspended in RNase-free water 
for a 20 nmole stock. MDA-468 cells (2.5 x 104) were plated on 6-well plates. To transfect the 
cells next day, we mixed 250 ul OptiMEM aliquots containing 30 pmol siSHIP2 and 5 ul 
Lipofectamine. We added the siSHIP2 plus Lipofectamine mix drop-wise into freshly replaced 2 
mL DMEM media with or without 1 ug/mL doxycycline.  
 
3.2.6 Trypan blue exclusion assay 
	
Cell death was determined by a trypan blue exclusion assay. Aliquots of 10 ul of both 
adherent and floating cell populations were collected and stained with 0.04% trypan blue (1:10 
dilution). Trypan blue stained dead cells and unstained live cells were counted using a 
hemacytometer to quantify percent cell death. 
 
3.2.7 Western blotting 
The same procedure described in Chapter 2.2.7 was used to perform Western blotting. 
The antibodies used in this study were: phospho-AKT (Ser473), total AKT, phospho-ERK 
(Thr202/204), total ERK, GAPDH (Cell Signaling), CIB1 [chicken polyclonal antibody, (63)], 
vinculin (Sigma). Phospho-SHIP2 (Ser132) and total SHIP2 antibodies were generously 
provided by the Erneux lab.  
 
3.2.8 Immunoprecipitation phosphatase assay 
The phosphatase activity of PP2A B56ε and SHIP2 was measured by Malachite Green 
phosphatase assays (Milipore 17-313). At the conclusion of treatments, about 3 x 106 cells were 
harvested and lysed with 400 ul buffer containing 10 mM CHAPS in HEPES pH 7.4. After 
incubating the lysed cells on ice for 30 min, 5 ul of antibody against PP2A B56ε (Milipore) or 
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SHIP2 (Cell Signaling) was added and incubated in rotation at 4 oC overnight. Protein A 
agarose beads were added to immunoprecipitate for PP2A B56ε and SHIP2. The 
immunoprecipitants were then subjected to the malachite green phosphate assay and quantified 
for phosphatase activity using plate reader in accordance to the kit procedure. 
3.3 Results 
3.3.1 Phosphoproteomic profiles of CIB1 depleted TNBC cells 
We previously reported that CIB1 regulates AKT and ERK pathways in TNBC cells and 
that depleting CIB1 inhibits both pathways to cause cell death (63, 66). Previous studies 
indicated that CIB1 does not seem to directly regulate AKT and ERK activity, but rather 
indirectly, possibly by binding upstream effectors PAK1 (61) and PDK1 (unpublished). In this 
study, we employed phosphoproteomic approaches to identify other players involved in the 
CIB1-AKT/ERK signaling cascade. We chose to analyze control or CIB1-depleted MDA-468 and 
MDA-231 TNBC cells, which are separated by sensitivity to CIB1 depletion. By profiling both 
CIB1 depletion-sensitive MDA-468 and insensitive MDA-231 TNBC cells, we aimed to identify 
differentially regulated signaling players as novel mechanism underlying sensitivity to CIB1 
depletion. 
 
Both MDA-468 and MDA-231 cells were previously engineered in the lab to allow 
depletion of CIB1 in a doxycycline-inducible manner. As shown in Figure 3-1A, we induced CIB1 
depletion upon addition of doxycycline (Dox). Downregulation of AKT (serine 473) and ERK 
(threonine-185/187) activity in response to doxycycline-induced CIB1 depletion was confirmed 
by Western blotting (Figure 3-1A). Subsequently, control and CIB1 depleted MDA-468 and 
MDA-231 cells were used to perform phosphoproteomic analysis. A total of 11,921 unique 
phosphorylation sites were identified. Ingenuity Pathway Analysis (IPA) of log2 fold changes in 
CIB1-depleted versus control cells identified 670 upregulated and 359 downregulated phospho-
sites in MDA-468 cells whereas 613 upregulated and 276 downregulated were identified in 
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MDA-231 cells (Figure 3-1B and Appendix F). Interestingly, we found only 41 upregulated and 3 
downregulated phospho-sites that overlap between the two TNBC cells. The lack of overlapping 
sites that are up or downregulated provides a general explanation as to why MDA-468 and 
MDA-231 cells are differentially sensitive to CIB1 depletion 
 
As expected, the phosphoproteomic analysis showed an approximately 8-fold 
downregulation of ERK threonine-185/187 in CIB1 depleted MDA-468 cells albeit with a p-value 
of 0.08 (Table 3-1). Due to the high log2 fold change in -2.72, it is expected that repeated 
experiments would result in a statistically significant change. Otherwise, we found that other 
MAPK proteins were significantly regulated upon CIB1 depletion to inhibit the ERK pathways 
(Table 3-1). The cleaved peptide containing AKT serine-473 phosphorylation site was not 
detected due to its length being over a detection limit set for the mass spectrometer of 15 amino 
acids. The predicted length of phospho-peptide containing AKT serine-473 was 14 amino acids, 
close to the maximal length. Our previous studies of CIB1 depletion halting the cell cycle (63) 
was also further validated by our phosphoproteomic analysis which revealed an increased 
activity of cell cycle pathway inhibitors (Table 3-1). For the first time, a novel link between CIB1 
and phosphatase was uncovered as we detected an increase in phosphorylation of PP2A and 




Figure 3-1. Phosphoproteomic analysis of CIB1 depletion-sensitive MDA-468 and 
insensitive MDA-231 TNBC cells. To identify new signaling players associated with CIB1 in 
regulating AKT and ERK pathways for cell viability, phosphoproteomic analysis was performed 
on TNBC cells with or without CIB1 depletion. A) Control and doxycycline (Dox)-induced CIB1-
depleted MDA-468 and MDA-231 cells were probed for AKT and ERK activities, CIB1 and 
GAPDH as a loading control. B) Volcano plot of either upregulated (red) or downregulated 
(blue) phospho-sites indicated by log2 fold > +2 or < -2 on the x-axis. Colored phospho-sites 




Table 3-1. Ingenuity Analysis Pathway (IPA) analysis of differentially regulated proteins	
Table	2 
Protein name Phospho site 
MDA-468  
Log2 fold  
MDA-231  
Log2 fold  
Pathway 





MAP kinase kinase kinase 3 S333 n/a +2.07 
MAP kinase kinase kinase 4 S643 n/a +3.25 
MAP kinase kinase kinase 7 S93 -3.48 n/a 
MAP kinase 14 T180/T182 +1.25 + 2.00 
MAP kinase kinase kinase kinase 4 S716 n/a +5.55 
MAP kinase kinase kinase kinase 4 S788 n/a +3.07 
Serine/threonine-protein kinase 10 S438 +2.00 n/a 
Serine/threonine-protein kinase 10 T185 +1.96 n/a 
Serine/threonine-protein kinase D3 S27 -3.82 n/a 
PP2A B'' subunit alpha S692 +2.81 -1.29 
Phosphatase 
PP2A B56 kDa alpha  S41 +1.58 +5.04 
PP2A B56 kDa delta  S89 -4.44 n/a 
PP2A B56 kDa epsilon  S33 +2.11 n/a 
PP2A B56 kDa epsilon  S34 +1.34 -1.58 
Protein phosphatase 4 regulatory 2 S58 +1.16 n/a 
SHIP2 S132 +2.09 n/a 
CDK inhibitor 1 S130 +3.56 n/a 
Cell cycle 
Retinoblastoma-associated protein T823 +2.18 n/a 
Wee1-like protein kinase T173 n/a - 5.71 
CDK 9 T186 n/a + 3.30 
CDK 12 S108 - 1.48 n/a 
*p-value = 0.08
71 
3.3.2 Increased phosphatase activity of PP2A B56ε is not necessary for CIB1-mediated AKT 
and ERK pathways and cell death  
As shown in Table 3-1, one of the phosphatases that was significantly phosphorylated in 
MDA-468 cell was PP2A subunit B56ε. Because the regulatory subunit B56 of PP2A is well 
known for inhibiting AKT and ERK pathways (137-139, 141), we examined whether increased 
phosphorylation of PP2A B56ε by CIB1 depletion is necessary for inhibiting AKT/ERK signaling 
and inducing cell death.  
 
First, we tested whether CIB1 depletion does in fact increase PP2A B56ε phosphatase 
activity. PP2A B56ε immunoprecipitants from control and CIB1 depleted MDA-468 cells were 
subjected to a phosphatase assay (Millipore). We detected an ~1.5-fold increase in PP2A B56ε 
phosphatase activity in CIB1 depleted versus control cells (Fig. 3-2A). Subsequently, we 
performed a loss-of-function study by using LB-100, an inhibitor of PP2A. We found that LB-100 
treatment, as expected, decreases PP2A B56ε phosphatase activity in CIB1 depleted cells (Fig. 
3-2B). We then asked whether PP2A B56ε inhibition via LB-100 reverses CIB1 depletion-
induced cell death and inhibition of AKT/ERK activities. Cell viability and AKT/ERK activities in 
CIB1 depleted cells were not rescued when we blocked PP2A B56ε phosphatase activity via 
LB-100 (Fig. 3-2C and 3-2D). Collectively, these results suggest that PP2A B56ε phosphatase 
activity is regulated by CIB1 but is not necessary for CIB1-mediated cell death or AKT/ERK 
pathways.  However, this leaves open the possibility that PP2A B56ε may contribute to CIB1’s 




Figure 3-2. Increased PP2A B56 epsilon phosphatase activity is not necessary for CIB1-
mediated cell viability nor AKT and ERK pathways. A) PP2A B56 epsilon 
immunoprecipitants from control of CIB1-depleted MDA-468 cells (Dox-induced CIB1KD) were 
measured for phosphatase activity via Malachite Green detection, n=2. B) CIB1-depleted cells 
were pre-treated with or without LB-100 (1 uM), a PP2A inhibitor, to block PP2A B56 epsilon 
phosphatase activity, n=1. The effect of LB-100 on CIB1 depletion-induced C) cell death and D) 
AKT and ERK activities was determined by a trypan blue exclusion assay and Western blotting, 
respectively (n=2).  
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3.3.3 CIB1 depletion increases SHIP2 expression, serine 132 phosphorylation and phosphatase 
activity 
Phosphoproteomic analysis in Fig. 3-1 revealed a significant phosphorylation of another 
phosphatase, SHIP2, at the serine-132 residue in MDA-468 but not MDA-231 cells. To validate 
this finding, we used Western blotting to probe for total and phosphorylated SHIP2 Serine-132 
in control and CIB1-depleted MDA-468 and MDA-231 cells. Our Western blotting results indeed 
validated the increase in SHIP2 Serine-132 phosphorylation in MDA-468 (4-fold) but not in 
MDA-231 cells (Fig. 3-3A). Additionally, total SHIP2 levels increased in MDA-468 cells (Fig. 3-
3A), suggesting that SHIP2 Serine-132 phosphorylation is due to an increase in SHIP2 
expression levels. Doxycycline-induced CIB1 knockdown was confirmed by probing for CIB1 
(Fig. 3-3A). Next, we asked whether CIB1 depletion increases SHIP2 phosphatase activity. As 
demonstrated in Fig. 3-2A and 3-2B, we immunoprecipitated SHIP2 and measured its 
phosphatase activity. Interestingly, we detected an approximately 4-fold increase in SHIP2 
phosphatase activity in CIB1-depleted versus control MDA-468 cells. Taken together, these 
results describe CIB1 as a novel regulator of serine-132 phosphorylation and phosphatase 




Figure 3-3. CIB1 depletion increases Ser132 phosphorylation and phosphatase activity of 
SHIP2. A) Increased SHIP2 Ser132 phosphorylation in CIB1-depleted MDA-468 cells (Dox-
induced CIB1KD) was confirmed by Western blotting (n=3). B) SHIP2 immunoprecipitants from 
control or CIB1-depleted MDA-468 cells were measured for phosphatase activity via Malachite 
Green detection (n=2).  
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3.3.4 Abrogating SHIP2 function does not reverse CIB1 depletion-induced inhibition of AKT and 
ERK activities and cell death 
Previous studies established that depleting CIB1 inhibits AKT/ERK activities and induces 
TNBC cell death (63, 66). In Figure 3-3, we found that CIB1 depletion increases SHIP2 
phosphorylation (serine-132) and phosphatase activity. Based on these results, we asked 
whether this novel link between CIB1 and SHIP2 is necessary for CIB1-mediated AKT/ERK 
signaling and TNBC cell viability. We used AS1949490 (AS19), a selective inhibitor of SHIP2 
(149), to block SHIP2 phosphatase activity and asked whether cell viability and AKT/ERK 
activity were rescued in CIB1-depleted MDA-468 TNBC cells. As a result, blocking SHIP2 
phosphatase activity via AS19 treatment had no effect on CIB1 depletion-induced TNBC cell 
death or inhibition of AKT/ERK activity (Fig. 3-4A and 3-4B). Consistent with Fig. 3-3A, CIB1 
depletion increased the total expression and serine-132 phosphorylation of SHIP2, regardless of 
AS19 treatment (Fig. 3-4B). These results indicate that increased SHIP2 phosphatase activity 
by CIB1 depletion is not necessary for regulating TNBC cell viability or AKT/ERK signaling. 
 
Aside from its phosphatase function, SHIP2 is also involved in acting as a scaffold to 
regulate receptor tyrosine kinases such as EGFR, Eph2A, and FGFR, which are known to 
mediate cell viability and AKT/ERK pathways (150-154). Therefore, we tested whether the 
increased SHIP2 expression in CIB1-depleted cells affected SHIP2 scaffold function. We used 
RNA interference to silence SHIP2 in control and CIB1 depleted MDA-468 cells, and measured 
cell death and AKT/ERK activities. We found that silencing SHIP2 did not rescue viability of 
CIB1-depleted cells (Fig. 3-4C). By Western blotting, we confirmed that the increased SHIP2 
expression upon CIB1 depletion was silenced by RNA interference (Fig. 3-4D). However, 
silencing SHIP2 had no effect on CIB1 depletion-induced inhibition of AKT and ERK activity. 
These results collectively suggest that the roles of SHIP2 as either a phosphatase or scaffold 




Figure 3-4. Inhibiting phosphatase activity and expression of SHIP2 does not alter CIB1 
depletion-induced cell death or downregulation of AKT/ERK activities. CIB1-depleted cells 
were pre-treated with or without AS-19, a selective SHIP2 inhibitor, and measured for A) cell 
death and B) AKT and ERK activities were measured in a trypan blue exclusion assay and by 
Western blotting, respectively (n=2). CIB1-depleted cells were transfected with or without 
siSHIP2 and measured for C) cell death and D) AKT and ERK activities, as demonstrated in A) 
and B) (n=2). 
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3.3 Discussion 
Currently, we do not have a sufficient understanding on signaling network around CIB1 
that connects to the oncogenic AKT and ERK pathways. Even though we established that CIB1 
regulates these AKT/ERK pathways, a detailed signaling mechanism that links CIB1 to AKT and 
ERK activities is lacking. We believe that a better understanding of how CIB1 regulates these 
oncogenic pathways that drive TNBC will further justify CIB1 as a viable target in TNBC. 
Therefore, we took a global approach via phosphoproteomics in collaboration with the Xian 
Chen lab to uncover novel CIB1-dependent proteins involved in AKT/ERK pathways. 
 
Our phosphoproteomic analysis of CIB1-depleted versus control TNBC cells uncovered 
previously unknown links to CIB1. One in particular that stood out was the role of CIB1 in 
regulating phosphatases such as PP2A B56ε and SHIP2. Both PP2A B56ε and SHIP2 
phosphatases are well studied in shutting off AKT/ERK pathways (137-141, 143, 144). This led 
us to further investigate the link between CIB1 and these phosphatases and whether this link is 
important for regulating AKT and ERK pathways. In this study, we were able to validate the 
phosphoproteomic results by showing that CIB1 depletion does in fact increase phosphatase 
activity of both PP2A B56ε and SHIP2. However, the increased phosphatase activity by CIB1 
depletion was determined to not be necessary for inhibiting AKT/ERK activities and promoting 
cell death.  
 
It is still possible that CIB1 regulates AKT/ERK signaling and cell viability via PP2A B56ε 
and SHIP2 through a mechanism independent of their phosphatase activities. Instead, 
subcellular localization of PP2A B56ε and SHIP2 mediated by CIB1 may be important for 
regulating AKT/ERK signaling and cell viability. For instance, the phosphorylation of PP2A B56 
leads to re-localization from the nucleus to the mitochondria, which can then trigger cell death 
signaling (155). In a separate study, the serine 132 phosphorylation of SHIP2, which we found 
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to be upregulated upon CIB1 depletion, causes re-localization to the cytoplasm and nuclear 
speckles (156). Such re-localization of SHIP2 away from the membrane may affect its scaffold 
ability to signal multiple RTK acting upstream of AKT and ERK pathways (145-148). In future 
studies, it will be interesting to investigate the effect of CIB1 depletion on the subcellular 
localization of PP2A B56 and SHIP2 as a potential mechanism for inhibiting AKT and ERK 
signaling and cell viability.  
 
Other than phosphatases, the cell cycle pathway is also differentially regulated in CIB1-
depleted MDA-468 versus MDA-231 cells. Our phosphoproteomic analysis revealed that 
inhibitors of the cell cycle such as cyclin-dependent kinase inhibitor 1 (CDKN1A) and 
retinoblastoma-associated protein (RB1) were upregulated selectively in MDA-468 cells. This 
result is consistent with a previous study by Leisner et al, which showed that CIB1 depletion 
halts the cell cycle in MDA-468 cells. Our phosphoproteomic results collectively suggest that 
upregulation of phosphatases and inhibitors of the cell cycle may explain why MDA-468 cells 
are sensitive to CIB1 depletion. Interestingly, such phosphatases and inhibitors of the cell cycle 
were not upregulated in CIB1 depletion-insensitive MDA-231 cells. This phenomenon may be 
similar in normal breast epithelial ME16C cells, which like MDA-231 cells, are insensitive to 
CIB1 depletion. Therefore, results from this study may provide new insights to mechanistically 
explain how ME16C normal cells are unaffected by CIB1 depletion to further support CIB1 as a 




Chapter 4: Future directions and conclusions 
4.1 Future directions 
For this study, we performed diverse experiments to mechanistically explain the effects 
of targeting CIB1 on cell death and phosphatase signaling. Even though this work strengthened 
CIB1 as a viable target in TNBC, we believe it also raises several interesting new questions, 
which are discussed here as future directions. 
 
In Chapter 2, we uncovered potent combination treatments involving CIB1 targeting. 
Using TNBC cells, we enhanced CIB1 depletion-induced cell death by combining it with the 
chemotherapeutic agent, docetaxel, or the cell death inducing ligand, TRAIL. These novel 
combinations helped to lower the effective dosages of docetaxel or TRAIL that are tolerable to 
normal breast epithelial cells; however, questions remain as to whether these results will 
translate into favorable toxicity profiles in vivo. Therefore, it will be important to test our 
combination treatments in vivo using various types of mouse models. We could use a previously 
established xenograft mouse model by injecting TNBC cells engineered with doxcycyline-
inducible shRNA to target CIB1. We may also use a genetically engineered mouse model 
(GEMM) to treat spontaneously generated tumors with a small molecule inhibitor against CIB1, 
which is currently under development. In either mouse model, we would examine the toxicity 
profile and survival in response to CIB1 targeting combined with docetaxel or TRAIL. 
Additionally, we would track the spread of TNBC tumors by luminescence imaging to determine 
whether the combination treatments lower metastatic potential.  
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In Chapter 3, we performed phosphoproteomic analysis to identify novel CIB1-
dependent signaling pathways that determine TNBC cells as either CIB1 depletion sensitive or 
insensitive. Even though phosphatases PP2A B56ε and SHIP2 were activated selectively in 
CIB1-depleted MDA-468, not MDA-231 cells, these phosphatase activities did not contribute to 
CIB1 depletion sensitivity. Instead, we believe that decoy receptor-2 (DcR2) may regulate 
sensitivity to CIB1 depletion. DcR2 inhibits TRAIL receptor-mediated cell death, shown in 
Chapter 2, as a mechanism for TNBC cells’ sensitivity to CIB1 depletion. Interestingly, CIB1-
depleted normal breast epithelial ME16C cells increased DcR2 expression, potentially 
explaining why ME16C normal cells are insensitive to CIB1 depletion. Since DcR2 signals NF-
κB pathway for survival, it is possible that CIB1 depletion-induced DcR2 expression in normal 
cells, unlike in TNBC cells, shifts the signaling from pro-death to pro-survival. Therefore, these 
preliminary results of how CIB1 differentially regulates DcR2 expression in TNBC versus normal 
cells will serve as a rationale for a separate study to investigate not only the NF-κB pathway but 
also its downstream target genes (IAP, XIAP, and c-FLIP) in this context. This would be part of 
a mechanism-based study involving DcR2 and NF-κB pathways, which may provide novel 
insight into how ME16C normal cells are protected from CIB1 depletion-induced cell death. 
 
We have demonstrated that targeting CIB1 can be an effective strategy for formulating 
therapeutics against TNBC. Future studies that mechanistically define CIB1 as a safe target will 






CIB1 is a promising target for its unique roles in cancer biology. In this dissertation, I 
have 1) demonstrated that targeting CIB1 via RNA interference in combination with 
chemotherapeutic agent docetaxel and cell death inducing ligand TRAIL further enhances 
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selective TNBC cell death and 2) mechanistically uncovered novel cell death and phosphatase 
signaling associated with targeting CIB1. 
 
TNBC patients have limited treatment options and often suffer from resistance and 
toxicity due to chemotherapy. To address these issues pre-clinically, we tested combination 
treatments involving CIB1 depletion with the aim of enhancing TNBC-selective cell death and 
overcoming chemo-resistance. CIB1 depletion combined with docetaxel significantly enhanced 
tumor-specific cell death relative to each treatment alone. The enhanced cell death strongly 
correlated with caspase-8 activation, a hallmark of death receptor-mediated apoptosis. The 
death receptor TRAIL-R2 was upregulated in response to CIB1 depletion, which sensitized 
TNBC cells to the ligand TRAIL, resulting in a synergistic increase in cell death. In addition to 
death receptor-mediated apoptosis, both combination treatments activated a non-apoptotic 
mechanism, called paraptosis. Interestingly, these combination treatments also induced nearly 
complete death of docetaxel-resistant MDA-MB-436 cells, again via apoptosis and paraptosis. 
In contrast, neither combination treatment induced cell death in normal ME16C cells. 
 
An additional project in collaboration with the Xian Chen lab aimed to map out the 
signaling network surrounding CIB1 via phosphoproteomic analyses. The goal of this project 
was to identify novel CIB1-dependent signaling pathways that contribute to CIB1 depletion-
induced cell death and inhibition of AKT and ERK activities. Interestingly, phosphoproteomic 
profiles of CIB1-depleted MDA-468 and MDA-231 TNBC cells showed remarkably different 
results with very few phosphorylation sites that are mutually up or down-regulated. The lack of 
profile overlap suggests why MDA-468 cells are sensitive while MDA-231 cells are insensitive to 
CIB1 depletion. More specifically, we were able to validate phosphoproteomic results of 
increased PP2A B56ε and SHIP2 phosphatase activity in MDA-468 but not MDA-231 cells. 
However, we found that activation of PP2A B56ε and SHIP2 by CIB1 depletion is not necessary 
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for regulating AKT/ERK pathways or cell viability. This project uncovered a novel association 
between CIB1 and phosphatases; however, we conclude that either nonenzymatic roles of 
these phosphatases or additional CIB1-dependent signaling players are required to regulate 
AKT/ERK pathways and TNBC viability.  
 
The selectivity in killing TNBC over normal cells makes CIB1 an intriguing target. Our 
efforts to determine the underlying mechanisms for selective TNBC killing led us to formulate a 
potent combination treatment of CIB1 depletion plus TRAIL. Such efforts to study cell death 
mechanisms are to be continued to explain how CIB1 targeting induces TNBC-selective cell 
death. We conclude by emphasizing the importance of studying cell death mechanisms in pre-
clinical studies to design potentially safe, efficacious therapies for TNBC and other cancers.  
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Combination of CIB1 depletion and docetaxel/TRAIL does not enhance autophagic 
signaling. Lysates from control or CIB1 depleted MDA-436 cells treated with either docetaxel 
(10 nM  & 35 nM) or TRAIL (5 ng/mL & 10 ng/mL) were probed for the marker of autophagy, LC-






CIB1 depletion in combination with docetaxel or TRAIL does not activate necroptotic 
signaling caspase-independent cell death. Control or CIB1-depleted cells were pretreated 
with vehicle (DMSO) or 50 µM z-VAD-fmk (z-VAD) for 24 h before adding 10 nM docetaxel or 10 
ng/ml TRAIL for an additional 48 h. Cell lysates were probed for phosphorylated RIPK1, a 
marker of necroptosis, and cleaved caspase-8 as a positive control to assure caspase inhibition 






Alix-1 overexpression alone or with z-VAD pre-treatment does not further rescue viability 
of MDA-436 cell treated with CIB1 depletion in combination with docetaxel or TRAIL. 
Naïve or Alix-1 overexpressing control or CIB1-depleted cells were pretreated with vehicle 
(DMSO) or 50 µM z-VAD-fmk (z-VAD) for 24 h before adding 10 nM docetaxel or 10 ng/ml 
TRAIL for an additional 48 h (N=3). A) Cell death was quantified via trypan blue staining. B) Cell 
lysates were probed for Alix-1, a negative marker of paraptosis, and cleaved caspase-8 as a 







CIB1 depletion alone or in combination with docetaxel or TRAIL does not activate NF-κB 
p65 but decreases IκB-α  activity in TNBC cells. Control or CIB1-depleted MDA-436 TNBC 
cells were treated with either docetaxel (35 nM) or TRAIL (10 ng/mL) for 48 h. Lysates were 
probed for phosphorylated and total NF-κB p65, IκB-α and loading control vinculin (n=2).  
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APPENDIX F: SELECTED PROTEINS WITH UP/DOWN-REGULATION 
 





Serine/threonine-protein kinase A-Raf ARAF_T256 -1.36 n.a. 
Serine/threonine-protein kinase A-Raf ARAF_S260 -0.01 n.a. 
Tyrosine-protein kinase Fyn FYN_S26 3.92 n.a. 
Tyrosine-protein kinase Fyn FYN_S21 3.83 n.a. 
Integrin alpha-3;Integrin alpha-3 heavy chain ITGA3_S1042 -1.48 n.a. 
Integrin beta-1 ITGB1_S785 0.84 n.a. 
Integrin beta-4 ITGB4_S193 1.53 n.a. 
Integrin beta-5 ITGB5_T780 0.83 n.a. 
Integrin beta-5 ITGB5_T782 0.16 n.a. 
MAP protein kinase kinase 2 MAP2K2_S196 0.49 n.a. 
MAP protein kinase kinase 2 MAP2K2_S198 0.49 n.a. 
Protein phosphatase 1 regulatory subunit 12A PPP1R12A_S527 1.46 n.a. 
Protein phosphatase 1 regulatory subunit 12A PPP1R12A_S409 3.78 n.a. 
Protein phosphatase 1 regulatory subunit 12C PPP1R12C_S383 -0.63 n.a. 
PP2A 56 kDa regulatory subunit alpha isoform PPP2R5A_S42 5.25 n.a. 
Protein kinase C alpha type PRKCA_S10 1.75 n.a. 
Protein kinase C alpha type PRKCA_S13 1.75 n.a. 
Protein kinase C iota type PRKCI_S8 2.60 n.a. 
Protein kinase C iota type PRKCI_T9 -2.80 n.a. 
Protein kinase C iota type PRKCI_S11 0.09 n.a. 
Paxillin PXN_S135 1.60 n.a. 
Paxillin PXN_S83 2.01 n.a. 
Paxillin PXN_S300 0.21 n.a. 
Paxillin PXN_S301 0.21 n.a. 
Ribosomal protein S6 kinase alpha-3 RPS6KA3_S715 0.33 n.a. 
Ribosomal protein S6 kinase alpha-4 RPS6KA4_S738 4.32 n.a. 
Ribosomal protein S6 kinase alpha-4 RPS6KA4_S734 2.24 n.a. 
Ribosomal protein S6 kinase alpha-4 RPS6KA4_S730 2.07 n.a. 
Ribosomal protein S6 kinase alpha-4 RPS6KA4_S343 1.07 n.a. 
Ribosomal protein S6 kinase alpha-4 RPS6KA4_S347 1.07 n.a. 
Ribosomal protein S6 kinase delta-1 RPS6KC1_S452 -0.79 n.a. 
Ribosomal protein S6 kinase delta-1 RPS6KC1_S455 -0.98 n.a. 
Serum response factor SRF_S21 0.54 n.a. 
Integrin beta-4 ITGB4_S41 n.a. 2.84 
Phostensin PPP1R18_S224 0.78 4.17 
Protein phosphatase inhibitor 2-like protein 3 PPP1R2P3_S95 2.40 3.09 
PP2A regulatory subunit B'' subunit alpha PPP2R3A_S692 -1.29 2.81 
PP2A 56 kDa regulatory subunit epsilon isoform PPP2R5E_S33 0.47 2.11 
Protein kinase C epsilon type PRKCE_S73 n.a. 3.43 
Protein kinase C epsilon type PRKCE_S69 n.a. 2.80 
Breast cancer anti-estrogen resistance protein 1 BCAR1_S280 n.a. 1.55 
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PP2A 56 kDa regulatory subunit alpha isoform PPP2R5A_S41 5.04 1.58 
PP2A 56 kDa regulatory subunit epsilon isoform PPP2R5E_S34 -1.58 1.34 
Paxillin PXN_S124 0.92 1.48 
Paxillin PXN_S128 0.48 1.48 
Serine/threonine-protein kinase A-Raf ARAF_S585 -0.24 0.73 
PP2A 56 kDa regulatory subunit delta isoform PPP2R5D_S89 3.85 -4.44 
Ribosomal protein S6 kinase alpha-3 RPS6KA3_T365 0.07 -2.99 
Ribosomal protein S6 kinase alpha-5 RPS6KA5_S381 n.a. -3.49 
Ribosomal protein S6 kinase alpha-5 RPS6KA5_S376 n.a. -3.71 
Protein phosphatase 1 regulatory subunit 3D PPP1R3D_S25 -0.33 -1.32 
Protein phosphatase 1 regulatory subunit 3D PPP1R3D_S28 -0.33 -1.32 
Serine/threonine-protein kinase A-Raf ARAF_S277 -3.83 1.29 
Serine/threonine-protein kinase A-Raf ARAF_S272 -4.08 0.16 
Serine/threonine-protein kinase B-raf BRAF_S337 0.47 0.48 
Dual specificity protein phosphatase 4 DUSP4_S300 2.49 0.61 
EIF 4E-binding protein 1 EIF4EBP1_S65 n.a. 0.45 
EIF 4E-binding protein 1 EIF4EBP1_T70 n.a. 0.45 
Integrin alpha-V light chain ITGAV_T1002 n.a. -0.93 
Integrin beta-1-binding protein 1 ITGB1BP1_S11 3.97 0.26 
Integrin beta-1-binding protein 1 ITGB1BP1_S13 n.a. 0.64 
MAP kinase kinase 2 MAP2K2_T297 -1.61 0.71 
Mitogen-activated protein kinase 1 MAPK1_Y187 -1.13 -2.72 
Mitogen-activated protein kinase 1 MAPK1_T185 -0.93 -2.72 
PI3K C2 domain-containing subunit alpha PIK3C2A_S259 -0.35 0.42 
PI3K C2 domain-containing subunit alpha PIK3C2A_S338 0.01 0.95 
Protein phosphatase 1 regulatory subunit 12A PPP1R12A_T637 -0.32 0.80 
Protein phosphatase 1 regulatory subunit 12A PPP1R12A_S299 2.33 1.12 
RelA-associated inhibitor PPP1R13L_S110 n.a. -1.14 
RelA-associated inhibitor PPP1R13L_S113 n.a. 1.45 
RelA-associated inhibitor PPP1R13L_S102 n.a. 2.31 
RelA-associated inhibitor PPP1R13L_S597 0.37 1.90 
RelA-associated inhibitor PPP1R13L_S526 1.14 0.75 
Protein phosphatase 1 regulatory subunit 14C PPP1R14C_S33 n.a. 1.57 
Protein phosphatase 1 regulatory subunit 37 PPP1R37_S128 -0.99 0.91 
Protein phosphatase 1 regulatory subunit 37 PPP1R37_S87 n.a. -0.59 
Protein phosphatase 1 regulatory subunit 37 PPP1R37_S88 n.a. -0.59 
Protein phosphatase 1 regulatory subunit 37 PPP1R37_S118 -0.68 1.89 
Protein phosphatase 1 regulatory subunit 37 PPP1R37_S124 -1.33 1.32 
Protein phosphatase 1 regulatory subunit 3D PPP1R3D_S77 n.a. 3.41 
Protein phosphatase 1 regulatory subunit 3D PPP1R3D_S46 1.61 0.46 
Protein phosphatase 1 regulatory subunit 3D PPP1R3D_S78 1.71 0.55 
Protein phosphatase 1 regulatory subunit 3D PPP1R3D_S74 2.96 0.55 
Protein phosphatase 1 regulatory subunit 7 PPP1R7_S33 2.89 -0.16 
Protein phosphatase 1 regulatory subunit 7 PPP1R7_S36 2.89 -0.16 
PP2A regulatory subunit B'' subunit alpha PPP2R3A_S562 n.a. 2.06 
PP2A regulatory subunit B'' subunit alpha PPP2R3A_S687 n.a. 3.49 
90 
PP2A regulatory subunit B'' subunit alpha PPP2R3A_S558 n.a. 2.02 
PP2A 56 kDa regulatory subunit delta isoform PPP2R5D_S88 -2.19 1.42 
PP2A 56 kDa regulatory subunit delta isoform PPP2R5D_S90 -2.17 2.29 
PP2A 56 kDa regulatory subunit epsilon isoform PPP2R5E_S32 0.47 1.99 
Protein kinase C beta type PRKCB_T497 1.03 0.00 
Protein kinase C delta type catalytic subunit PRKCD_S304 n.a. -0.13 
Protein kinase C delta type catalytic subunit PRKCD_Y313 n.a. -0.13 
Protein kinase C delta type catalytic subunit PRKCD_S506 -0.15 1.11 
Protein kinase C delta type catalytic subunit PRKCD_T507 0.62 0.94 
Paxillin PXN_S104 0.77 1.63 
RAF1  RAF1_S168 -0.30 0.56 
RAF1  RAF1_S180 0.05 0.37 
Ribosomal protein S6 kinase alpha-1 RPS6KA1_T17 0.79 -3.57 
Ribosomal protein S6 kinase alpha-1 RPS6KA1_S27 n.a. -4.05 
Ribosomal protein S6 kinase alpha-1 RPS6KA1_S21 0.91 -3.57 
Ribosomal protein S6 kinase alpha-3 RPS6KA3_S369 0.07 -2.47 
Ribosomal protein S6 kinase delta-1 RPS6KC1_S211 -0.70 -1.33 
Ribosomal protein S6 kinase delta-1 RPS6KC1_S215 -0.70 -1.25 
Ras-related protein R-Ras2 RRAS2_S185 0.47 2.27 
Proto-oncogene tyrosine-protein kinase Src SRC_S17 -0.72 0.84 
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